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Preface 
Preface 
 
In the 1990s life used to be simple. The entire family watched Formula 1 on Sunday 
afternoons and we still didn’t know what garbage recycling was. In an interesting analogy, 
biologists in the 90s thought of protein kinase A (PKA) as the only link between the second 
messenger cAMP and CFTR (first reported by Cheng et al. in 1991). Our data challenge 
this linear and somewhat simplistic view unveiling a novel relationship between CFTR and 
yet another cAMP effector, the exchange protein directly activated by cAMP (EPAC). We 
propose EPAC as a new player to the CFTR race circuit, a rally that begins in the 
endoplasmic reticulum, where the protein is translated, and finishes at the plasma 
membrane (PM), where the channel exerts its function. EPAC is involved in a number of 
cellular functions such as the regulation of cell-to-cell and cell-matrix adhesion and 
cytoskeleton rearrangements, processes that affect CFTR regulation.  Here we present 
compelling evidence suggesting that cAMP (here replaced by an analogue that does not 
activate the PKA pathway) promotes the interaction of EPAC with CFTR with the aid of the 
protein adaptor NHERF1. The formation of this complex increases the stability of CFTR at 
the PM. 
Using a multidisciplinary approach, we show that EPAC1 (the most abundant of the two 
EPAC isoforms known) and CFTR co-localize in cystic fibrosis bronchial epithelial cells 
(CFBE) – reporting this interaction in different airway epithelial cell lines that express 
endogenous EPAC1, namely A549, CFBE and Calu3. Cyclic AMP promotes EPAC 
translocation to the PM, in a CFTR-independent manner, as well as its interaction with 
CFTR. siRNAs or shRNAs against ezrin or NHERF1, proteins involved in the tethering of 
PKA in the proximity of CFTR, show that the latter (but not the previous) mediates the 
interaction between EPAC1 and CFTR. However, neither of these scaffolding proteins 
affects the translocation of EPAC1 to the PM. On the other hand, CFTR biotinylation at the 
PM shows that EPAC activation decreases CFTR endocytosis and promotes CFTR 
stabilization at the PM. Transient knockdown of EPAC1 has an opposite effect on CFTR 
stability. Additionally, EPAC activation does not affect CFTR total protein levels or the 
CFTR processing efficiency. Finally, the presence of the most common CFTR mutation, 
F508del, seems to affect levels of endogenous EPAC activation and EPAC-mediated cell 
adhesion.  
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In this way, a new link between CFTR regulation and cAMP was established. This novel 
player on the CFTR race circuit may contribute to a finer and more complex regulation of 
this channel. Definitely, life has just become more complicated. 
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Abstract 
 
CFTR, Cystic Fibrosis Transmembrane Conductance Regulator, is a chloride channel 
expressed in the apical membrane of epithelial cells. The malfunction of this protein is 
responsible for cystic fibrosis, the most common lethal autosomal recessive disease in the 
Caucasian population. One of the numerous proteins that interacts with CFTR and also 
regulates the function of this channel through phosphorylation is protein kinase A (PKA). 
Because PKA activity is cAMP-dependent, this kinase has been recognized as the link 
between this second messenger and CFTR. However, PKA is not the only cAMP sensor 
within the cell.  
EPAC, an exchange protein directly activated by cAMP, is another cAMP effector, involved 
in a number of cellular functions such as the regulation of cell-to-cell and cell-matrix 
adhesion, cytoskeleton rearrangements and cell polarization, processes that affect CFTR 
regulation and are defective in CF. The aim of this work was to characterize the interaction 
between CFTR and the most predominant isoform of EPAC, EPAC1, and to evaluate the 
impact of this cAMP sensor on CFTR biogenesis, trafficking and plasma membrane (PM) 
anchoring. 
Using a multidisciplinary approach, our results show that EPAC1 and CFTR co-localize 
and co-immunoprecipitate in airway epithelial cells. The second messenger cAMP 
promotes EPAC1 translocation to the PM and its interaction with CFTR. The adaptor 
protein NHERF1, but not ezrin, mediates the interaction between EPAC1 and CFTR. 
Furthermore, EPAC activation does not affect CFTR total protein levels or CFTR 
processing efficiency but promotes CFTR stabilization at the PM. Additionally, the 
presence of the most common CFTR mutation, F508del, seems to affect EPAC activity 
and EPAC-mediated cell adhesion. Thus, this work provided an important characterization 
of a new CFTR interacting protein that links cAMP to cystic fibrosis modulation in a 
previously unreported mechanism.  
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Resumo 
 
A Fibrose Quística (FQ), a doença recessiva autossómica letal mais comum na população 
caucasiana, é caracterizada por uma grave disfunção da função pulmonar causada pela 
obstrução das vias respiratórias devido à acumulação de muco e consequentes infecções 
bacterianas. A FQ é causada por mutações no gene que codifica para uma glicoproteína 
com 1480 resíduos de aminoácidos, designada CFTR (Cystic Fibrosis Transmembrane 
Conductance Regulator). Esta proteína, presente na membrana apical de células 
epiteliais, actua como um canal de cloreto. Até à data, foram identificadas cerca de 2000 
mutações possíveis causadoras da doença, sendo a mais comum a delecção de três 
nucleótidos que correspondem ao resíduo de feninalanina na posição 508 da proteína 
(F508del).  
Durante a sua síntese proteica, a proteína CFTR é inserida co-traducionalmente na 
membrana do retículo endoplasmático, onde adquire a sua conformação nativa, devido à 
acção de vários chaperones, e passa por um processo de glicosilação inicial. Daqui, é 
transportada para o Golgi onde os seus resíduos glicídicos são modificados, originando a 
sua forma madura. Posteriormente, é transportada em vesículas para a membrana 
plasmática (PM) onde exerce a sua função. Aqui, a proteína CFTR é endocitada sendo 
depois reciclada de volta para a PM ou enviada para degradação lisossomal. O equilíbrio 
entre estes processos é crucial para a quantidade de proteína presente na membrana. 
Na PM, a proteína CFTR pode estar ancorada a filamentos de actina, o que contribui para 
a sua estabilidade membranar. A proteína CFTR, através da sua região C-terminal, 
interage com várias proteínas com um domínio PDZ, nomeadamente a proteína 
adaptadora NHERF1 (Na+/H+-exchanger regulatory factor isoform 1), que por sua vez 
interage com proteínas do citoesqueleto, tal como a ezrina. Desta forma, o complexo 
CFTR-NHERF1-ezrina-actina contribui para a imobilização e ancoragem da proteína 
CFTR na PM, prevenindo a sua endocitose. Dessa forma, a ancoragem da CFTR na 
superfície celular é uma importante via a ser considerada em termos da intervenção 
terapêutica em doentes com FQ. 
Uma vez na PM, a proteína CFTR está envolvida na regulação do transporte transepitelial 
de iões e água. A abertura do canal CFTR é regulada pela fosforilação catalisada pela 
proteína cinase A (PKA) em resposta a um aumento local dos níveis de AMP cíclico 
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(cAMP). A compartimentalização do cAMP depende da integridade do citoesqueleto e é 
essencial para um aumento da especificidade e eficiência da sinalização deste 
mensageiro secundário. Uma vez que a actividade da PKA é dependente dos níveis de 
cAMP, esta cinase tem sido reconhecida como a ligação entre a proteína CFTR e o 
cAMP. No entanto, a PKA não é o único sensor de cAMP que existe na célula; a proteína 
EPAC (exchange protein directly activated by cAMP) também actua como um efector do 
cAMP. 
  
A proteína EPAC funciona como um factor de troca de nucleótidos de guanina para a 
Rap, uma pequena GTPase (enzima que hidrolisa GTP) da família Ras. Esta GTPase 
está activa quando ligada a GTP e inactiva quando ligada a GDP. Assim, a proteína 
EPAC promove a activação deste interruptor molecular, já que leva à ligação de GTP. Em 
resposta ao aumento dos níveis de cAMP, a proteína EPAC transloca do citosol para a 
PM, onde pode activar a Rap. A interacção com a PM pode ser feita de uma forma 
dependente de ácido fosfatídico ou através da proteína do citoesqueleto ezrina. Esta 
informação sugere que a proteína EPAC pode co-localizar, ou até mesmo interactuar, 
com a proteína CFTR, e, possivelmente, regular a sua função ou estabilidade membranar. 
A proteína EPAC está envolvida em várias funções biológicas, principalmente devido às 
várias localizações sub-celulares que esta proteína pode ter e aos vários parceiros 
moleculares com que pode interagir. Nomeadamente, está envolvida na regulação da 
adesão célula-célula ou célula-matriz, organização do citoesqueleto ou polarização celular 
- processos que afectam a regulação da proteína CFTR, e que estão em geral alterados 
na FQ. Desta forma, o objectivo deste trabalho consistiu em caracterizar a interacção 
entre a proteína CFTR e a principal isoforma da proteína EPAC, a EPAC1, e avaliar o 
impacto deste sensor de cAMP na biogénese, tráfego e ancoragem da CFTR na PM. 
O primeiro passo do trabalho consistiu em avaliar se o composto 007-AM de facto actua 
como um análogo do cAMP específico para a EPAC (e não PKA). Este estudo, bem como 
outros posteriores, foi realizado em células CFBE (Cystic Fibrosis Bronchial Epithelial) de 
forma a melhor mimetizar os processos que ocorrem no epitélio brônquico de pacientes 
com FQ. Outras linhas celulares de epitélio respiratório também usadas foram as linhas 
Calu3 (de glândula submucosa) e A549 (alveolar). A análise por FRET mostrou que o 
sensor dos níveis de cAMP baseado na estrutura da EPAC sofre grande alteração da 
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percentagem de FRET, o mesmo não se observando com o sensor da actividade da PKA 
– o que permitiu evidenciar a selectividade do 007-AM para a EPAC. A activação da 
proteína EPAC, em resultado do tratamento das células com 007-AM, promove a sua 
translocação para a PM, em células CFBE, de uma forma independente da proteína 
CFTR. Além disso, usando um sensor FRET da actividade da EPAC e um ensaio para a 
actividade da Rap1A (uma das isoformas da Rap), observou-se que células que 
expressam CFTR WT (wild-type) apresentaram um aumento de FRET na PM após 
tratamento com 007-AM, enquanto células que expressam CFTR F508del tendem a ter 
níveis mais elevados de Rap1A na forma activa. O tratamento com 007-AM promove 
também um aumento dos níveis de Rap1A activa em células que expressam CFTR WT 
mas não nas que expressam CFTR F508del. 
Adicionalmente, o tratamento com 007-AM promoveu a adesão celular em células que 
expressam CFTR WT mas não nas células que expressam CFTR F508del. Isto sugere 
que, em células que expressam CFTR com esta mutação, a via EPAC-Rap não consegue 
exercer a sua função e, de forma a ultrapassar esta limitação, a activação endógena da 
EPAC se encontra aumentada. Consequentemente, uma activação adicional não é 
detectada, dados os elevados níveis basais de activação. 
  
De seguida, a possível co-localização e interacção entre as proteínas CFTR e EPAC1 foi 
avaliada. Para isso, recorreu-se a microscopia confocal de fluorescência e a ensaios de 
co-imunoprecipitação. Observou-se que a EPAC1 co-localiza e interage com CFTR, quer 
na sua forma WT quer na sua forma mutada. Além disso, a activação da EPAC com 007-
AM aumentou a interacção entre CFTR e EPAC1. No entanto, a activação da EPAC1 não 
afecta a razão de CFTR na forma madura e forma imatura (que permite avaliar a 
eficiência de processamento da CFTR). Estes dados sugerem que a EPAC não está 
envolvida na fase inicial da biogénese da CFTR (síntese, folding e processamento inicial). 
Observámos também que a depleção de NHERF1 (usando siRNA ou shRNA), mas não 
de ezrina, impediu a interacção entre a CFTR e a EPAC1 mas sem afectar a localização 
sub-celular da última. Isto sugere que a interacção entre estas duas proteínas é mediada 
pela proteína adaptadora NHERF1. 
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Finalmente, recorreu-se a ensaios de endocitose e biotinilação para avaliar o efeito da 
EPAC1 na estabilidade da CFTR na PM. Observou-se que a activação da EPAC decresce 
a quantidade de CFTR que é internalizada ao longo do tempo. Além disso, o tratamento 
com 007-AM levou a um aumento dos níveis de CFTR na PM enquanto a depleção da 
EPAC1 usando siRNA diminuiu estes níveis. Adicionalmente, a sobreexpressão de EPAC 
parece também promover a estabilidade da CFTR. Estas abordagens sugerem que a 
EPAC1 está envolvida na regulação da estabilidade da CFTR na PM.  
Este efeito estabilizador permite também um aumento da quantidade de proteína CFTR 
F508del madura detectada após o tratamento simultâneo com o corrector de tráfego VX-
809 e o agonista 007-AM. 
 
Apesar dos avanços recentes no campo da FQ, ainda existem vários aspectos do tráfego 
e activação da CFTR por elucidar e parceiros moleculares por identificar. Desta forma, os 
resultados deste trabalho permitiram identificar uma nova ligação entre a proteína CFTR e 
a sinalização por cAMP. Este trabalho constitui assim uma importante caracterização de 
um novo interactor da CFTR, a proteína EPAC1, que liga o cAMP à modulação da FQ, por 
mecanismos até à data não descritos.  
 
Abbreviations 
 
xiii 
 
Abbreviations 
 
007   8-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate (8-pCPT-2’-O-Me-cAMP) 
007-AM  8-(4-Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate acetoxymethyl ester (8-pCPT-2’-O-Me-cAMP-AM) 
A549   Human alveolar epithelial cell line 
ABC   ATP-binding cassete 
AC   Adenylyl cyclase 
AKAP   A-kinase anchoring proteins 
AKAR4  A-kinase activity reporter 4 
ASL   Airway surface liquid 
ATF   Arginine-framed tripeptide 
ATP   Adenosine triphosphate 
BSA   Bovine serum albumin 
CAAX   Cystein-alyphatic-alyphatic-any aminoacid motif 
CaCC   Calcium-activated chloride channel 
cAMP   Cyclic adenosine monophosphate 
Calu-3   Cancer lung 3 cell line 
camps   cAMP sensor 
CDC25-HD  Cell division cycle 25 homology domain 
CF   Cystic fibrosis 
CFBE41o- / CFBE Cystic fibrosis bronchial epithelial cell line 
CFP   Cyan fluorescent protein 
CFTR   Cystic fibrosis transmembrane conductance regulator 
CNB   Cyclic nucleotide–binding domain 
COP-II   Coating protein II 
C-terminal  Carboxyl-terminal 
DAPI   4',6-diamidino-2-phenylindole 
DEP   Disheveled, Egl-10, pleckstrin domain 
DNA-PK  DNA damage–responsive kinase 
DMSO   Dimethylsulfoxide 
E3KARP  NHE3 kinase A regulatory protein 
EBP50   Ezrin-binding protein 
Abbreviations 
xiv 
 
EDEM   ER degradation-enhancing α-mannosidase-like protein 
EDTA   Ethylenediaminetetraacetic acid 
EMEM   Eagle’s minimal essential medium 
ENaC   Epithelial sodium channel 
EPAC/REPAC  Exchange protein directly activated by cAMP 
ER   Endoplasmic reticulum 
ERAD   Endoplasmic reticulum-associated protein degradation 
ERM   Ezrin/radixin/moesin 
ERQC   Endoplasmic reticulum quality control 
ESI-09   3-[5-(tert.-Butyl)isoxazol-3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-
oxopropanenitrile 
F-actin   Filamentous actin 
FBS   Fetal bovine serum 
FLIM   Fluorescence lifetime imaging 
FRET   Fluorescence resonance energy transfer 
Frsk   Forskolin 
GAP   GTPase-activating protein 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GDP   Guanosine diphosphate 
GEF   Guanine nucleotide exchange factor 
GFP   Green fluorescent protein 
GRASP  Golgi reassembly stacking protein 
GST   Glutathione S-transferase 
GTP   Guanosine triphosphate 
GTPase  Guanosine triphosphate hydrolase 
HBSS   Hank's Balanced Salt Solution 
HEK   Human embryonic kidney cell line 
HRP   Horseradish peroxidase 
Hsc70/Hdj2  Heat shock cognate 70kDa protein/human DnaJ homolog 2 
Hsp70/Hdj-1  Heat shock protein 70kDa protein/human DnaJ homolog 2 
Hsp90   Heat shock protein 90kDa protein 
HUVEC  Human umbilical vein endothelial cell line 
IBMX   3-isobutyl-1-methylxanthine 
If   Fluorescence intensity 
Abbreviations 
 
xv 
 
IP   Immunoprecipitation 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
LB   Luria broth 
MAP1   Microtubule-associated protein 1 
MSD   Membrane-spanning domain 
NBD   Nucleotide binding domain 
NHERF  Na+/H+-Exchanger Regulatory Factor 
N-terminal  Amino-terminal 
ORCC   Outwardly rectifying chloride channel 
P60   Plates with 60mm of diameter 
P100   Plates with 100mm of diameter 
PAGE   Poliacrylamide gel electrophoresis 
PBS   Phosphate buffer saline 
PBS-T   Phosphate buffer saline with tween 
PCR   Polymerase chain reaction 
PDE   Phosphodiesterase 
PDE4D3  Phosphodiesterase 4D3 
PDZ   Post synaptic density protein (PSD95), Drosophila disc large tumor 
suppressor (Dlg1), and zonula occludens-1 protein (zo-1) 
Pen   Penicilin 
PKA   Protein kinase A 
PM   Plasma membrane 
PP2A   Protein phosphatase-2A 
PPase   Protein phosphatase 
PVDF   Polivinylidene difluoride 
RA   Ras-association domain 
RanBP2  Ran-binding protein 2 
RBD   Rap-binding domain 
RD/R domain  Regulatory domain 
REM   Ras exchange motif domain 
RFP   Red fluorescent protein 
RFU   Relative fluorescence units 
RNA   Ribonucleic acid 
ROCK   RhoA-activated kinase 
Abbreviations 
xvi 
 
ROMK   Renal outer medullary potassium channel 
R-ras   Ras-like small GTPase 
RT   Room temperature 
SBT   Spectral bleed-through 
SDS   Sodium dodecylsulphate 
SEM   Standard error of the mean value 
shRNA   Small hairpin RNA 
siRNA   Small interfering RNA 
Strep   Streptomycin 
TBS   Tris buffer saline 
TBS-T   Tris buffer saline with tween 
TM   Transmembrane segments 
TNF-R1  Tumor Necrosis Factor Receptor 1 
Tris   Tris(hydroxymethyl)aminomethane 
UGGT   UDPglycoprotein glucosyltransferase 
YFP   Yellow fluorescent protein 
WB   Western Blot 
WCL   Whole cell lysates 
WT   Wild-type 
 
  
 
 
 
 
                             Chapter I 
Introduction 
  
  
  
Introduction 
1 
 
1. Introduction 
1.1 Cystic Fibrosis - Overview 
Cystic Fibrosis (CF) is the most common potentially lethal autosomal recessive disorder in 
Caucasians, affecting about 1 in 2500-6000 newborns. Remarkably, the heterozygote 
frequency is about 1 in 25 individuals1. CF is clinically characterized by chronic lung 
disease, which is the main cause of morbidity and mortality. Airway obstruction by thick 
mucus and chronic infection by Pseudomonas aeruginosa eventually lead to loss of 
pulmonary function2. Other CF symptoms include pancreatic dysfunction, elevated salt 
concentration in sweat and male infertility3. 
 
1.2 The CFTR gene and protein 
In 1989, the gene responsible for CF was identified to be located at the long arm of 
chromosome 7 (7q.31.2) and named Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR)4. This gene encodes for a cyclic AMP (cAMP)-regulated chloride 
channel expressed in a number of epithelial tissues. It was found to harbor mutations in all 
CF patients analyzed, the most common of which being a deletion of three nucleotides 
encoding for the phenylalanine residue in position 508 in the protein (F508del)5. This 
mutation is present in 90% of CF patients in at least one of their two mutated CFTR 
alleles. 
Gene sequence and direct mutation analysis were turning points in the history of CF and 
opened new opportunities for molecular and cellular studies in this field. To date, ~2000 
CFTR mutations have been described, most of which cause CF6.  Between these gene 
defects and the ultimate clinical phenotype of respiratory insufficiency, a series of events 
that have termed the ‘CF pathogenesis cascade’, sequentially occurs (Figure 1.1)2. To 
better understand the diversity of mechanisms through which single mutations cause CF, 
CFTR mutants are grouped into functional classes, according to their specific effects upon 
CFTR biosynthesis and function – and this allows the design of ‘mutation-specific 
therapy’7. Class I mutations abolish protein production. Class II mutations result in 
defective protein processing (F508del mutation belongs to this class). Class III proteins are 
defective in the regulation of the channel. Class IV mutations are characterized by 
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defective ion conductance. Class V mutations result in decreased protein synthesis. Class 
VI mutations decrease CFTR stability at the cell surface2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Mechanism of CF dysfunction. (a) The CF pathogenesis cascade, from the primary 
CFTR gene defect to lung deficiency. (b) Classes of defects in the CFTR gene include the absence 
of synthesis (class I); defective protein maturation and premature degradation (class II); altered 
regulation, such as diminished ATP binding and hydrolysis (class III); defective chloride 
conductance or channel gating (class IV); reduced amount of CFTR transcripts/protein due to 
promoter or splicing abnormality (class V); and accelerated turnover from the cell surface (class 
VI)
2, 3
. 
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Currently, search of new potential therapeutic targets and pharmacological therapies to 
rescue the molecular defects responsible for CF are the most important topics of disease-
related research2. In 2012, Kalydeco (developed as VX-770) was approved by the Food 
and Drugs Administration (USA), and later by the European Medicines Agency, as the first 
drug targeting the molecular basis of the disease (first mutation-specific therapy). This 
compound, that corrects the gating defect caused by several mutations on CFTR, has 
been approved initially for patients carrying the G551D gating mutation8 and more recently 
for other Class III/IV mutations. Ongoing clinical trials are exploring a combination of VX-
770 with others compounds, namely VX-809, that corrects the trafficking defect of CFTR 
with other mutations, such as F508del9. Thus, approaches aimed at correcting the basic 
CF defect still hold promise for completely curing the disease.  
The CFTR gene directs the synthesis of transcripts of about 6.5kb (after splicing) and 
encodes for an integral membrane glycoprotein composed of 1480 amino acids4, 10. The 
CFTR protein functions as a chloride channel predominantly expressed at the apical 
membrane of epithelial cells lining the target organs: lung, pancreas, intestine and sweat 
gland2. As a member of the ATP-binding cassette (ABC) transporter superfamily, CFTR 
has a symmetrical multi-domain structure, consisting of two membrane spanning domains 
(MSD1 and MSD2), each composed of six transmembrane segments (TM1-TM12) which 
form the pore through which anions pass, and two nucleotide-binding domains (NBD1, 
which harbors F508del mutation, and NBD2)5. Both NBDs bind and hydrolyze ATP, 
regulating the channel opening11. CFTR structure also contains a central and highly 
charged regulatory (R) domain, absent from all other ABC transporters, with multiple 
phosphorylation consensus sites (Figure 1.2)10, 12. The phosphorylation status of this 
domain may regulate the dimerization of the NBDs domains13. CFTR C-terminus, well 
known for accommodating a PSD95, Dlg1, ZO-1 (PDZ)-binding motif, is also involved in 
several protein interactions14.  
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Figure 1.2:  CFTR structure at the plasma membrane. MSD, membrane spanning domains; RD, 
regulatory domain (contains multiple phosphorylation sites); NDB, nucleotide-binding domain 
(NDB1 harbors the most frequent CF-causing mutation, F508del)
10
. 
 
1.3 CFTR folding and trafficking 
Although CFTR folding is a highly regulated process, because CFTR is such a large 
multidomain membrane glycoprotein, proper folding is difficult to achieve. Hereupon, 
during CFTR biogenesis, only 20-40% of the newly synthesized protein escapes the 
endoplasmic reticulum (ER) quality control (ERQC), undergo complex glycosylation in the 
Golgi complex and acquire the native conformation. The remaining protein is tagged for 
degradation by the ubiquitin-proteasome pathway15, 16. Thus, the coordinated folding of 
CFTR and its individual domains occur through an iterative process in three different 
cellular compartments: ER membrane and lumen, as well as cytosol17. 
Similarly to what happens with other multidomain glycoproteins, CFTR is co-translationally 
inserted into the ER membrane and simultaneously N-linked to glycosyl groups. 
Additionally, as a membrane protein, CFTR follows the general route of the secretory 
pathway to reach the plasma membrane (PM), i.e. through the Golgi10. 
In this way, while CFTR is being translated in a cytosolic ribosome, an ER targeting motif 
is recognized by the signal recognition particle, causing it to be targeted to the ER surface 
and co-translationally inserted into the ER membrane through the Sec61 translocon 
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complex17. While the nascent polypeptide chain is being inserted in the ER membrane, the 
exposed parts in the cytosol associate with the cytosolic molecular chaperones Hsp90, 
Hsc70/Hdj-2, and Hsp70/Hdj-1 (with this forming a first checkpoint in the ER quality control 
(ERQC) for CFTR; Figure 1.3)10, 18. Immediately after insertion into the ER membrane, the 
newly synthesized CFTR polypeptide chain emerging into the ER lumen is core-
glycosylated at Asn894 and Asn900. CFTR N-glycosylation, which occurs by the addition 
of a glycoconjugate with 14 osidic residues, plays a pivotal role in its folding, sorting and 
trafficking10, 18. This glycoconjugate is processed by glucosidases generating a 
glycosylated intermediate recognizable by luminal calnexin and calreticulin chaperones 
that allow the folding to progress (second checkpoint)15, 19. After these two initial ER folding 
checkpoints, CFTR conformation is assessed at a third checkpoint. This is a retention 
mechanism that recognizes arginine-framed tripeptide (ATFs) motifs at the ER exit sites. 
From this point, in the ER, there are two different pathways: 
-If the protein didn’t attain the proper folding, it is recognized by UDPglycoprotein 
glucosyltransferase (UGGT), which re-glycosylates CFTR. Hereupon, a new round of 
chaperone binding, de-glucosylation and proofreading begins. If the protein undergoes too 
many of these rounds, eventually it becomes subject to the ubiquitination-dependent 
endoplasmic-reticulum-associated protein degradation (ERAD). After being marked by the 
ER degradation-enhancing α-mannosidase-like protein (EDEM) for degradation, CFTR is 
retro-translocated to the cytoplasm and degraded by the ubiquitin-proteasome pathway10, 
15. Most of the CFTR bearing the F508del mutation, owing to its incorrect folding, is 
retained and degraded at the ER due to the ERQC system10; 
-If the protein is folded correctly, it proceeds to the secretory pathway. CFTR is released 
from the ER, loaded into COPII-coated vesicles that traffic to the Golgi, where its glycan 
moieties undergo further processing. The fully glycosylated CFTR is then incorporated into 
secretory vesicles and delivered to the apical membrane, exposing its glycans to the 
extracellular space and exerting its function10. More recently, ER stress was reported to 
induce CFTR trafficking from the ER to the apical membrane through a Golgi-independent 
GRASP-dependent unconventional secretion pathway20. 
During the maturation process, CFTR undergoes several glycosylation steps, first in the 
ER and then in the Golgi apparatus. For CFTR, glycosylation at the ER creates the core-
glycosylated 135-140kDa (immature) form of the protein (also called band B). From the 
ER, wild-type (WT) CFTR traffics through the Golgi complex, where it is processed by 
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multiple Golgi glycosyltransferases and glycosidases, creating the fully 150-160kDa 
mature form of CFTR (also termed band C)10, 16. 
 
 
Figure 1.3: Checkpoints for the ER quality control of CFTR. At the first checkpoint, Hsc70 and 
Hsp70 interact with the cytosolic domains of nascent CFTR to assess its conformation – this is the 
major mechanism for retaining and discarding F508del-CFTR. At the second checkpoint, WT-CFTR 
proceeds through the folding pathway through interaction of its N-glycosyl residues with calnexin. 
After the third checkpoint (retention mechanism that recognizes arginine-framed tripeptide (AFT) 
motifs), correctly folded CFTR exits the ER, proceeding through the secretory pathway. Ub, 
ubiquitin
10
. 
 
Additionally, after being delivered to the PM, CFTR can be subjected to endocytosis. 
CFTR is internalized into early endosomes where it can either return to the PM, through 
Rab11/MyoVb-driven recycling endosomes, or diverted from the recycling pathway into 
late endosomes, via Rab7, followed by lysosomal degradation21-23. As CFTR internalization 
at the cell surface is a rapid process compared to CFTR biosynthesis and maturation, the 
recycling of internalized channels is considered to be a key process in maintaining a 
functional pool of CFTR at the PM10. 
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1.4 CFTR anchoring at the plasma membrane 
Recycling of internalized CFTR to the PM has been considered to be the main mechanism 
for sustaining a functional pool of CFTR at the cell surface, albeit some evidence suggest 
that up to 50% of surface CFTR exists in an immobile pool, tethered to filamentous actin 
(F-actin), in airway epithelial cells10, 24. Because the CFTR C terminus (amino acids 
residues DTRL) forms a consensus PDZ binding domain (C-terminal X-[S/T]-X-[V/I/L]), it 
can bind to several proteins that contain these PDZ domains24, 25. One of these C-
terminus-interactors is the PDZ adaptor protein Na+/H+-exchanger regulatory factor 
isoform-1 (NHERF-1, also known as EBP50, ezrin-binding protein, 50kDa)26-28. NHERF-1 
anchors CFTR at the PM to the actin cytoskeleton and is also important to target 
exosome- and endosome associated CFTR to the apical membrane of polarized epithelial 
cells. The first involves the interaction of CFTR-bound NHERF-1 with the 
ezrin/radixin/moesin (ERM) family protein ezrin, locking CFTR in an immobile and actin-
tethered complex that prevents its endocytosis (Figure 1.4)10, 26. NHERF1 increases the 
chloride channel activity of CFTR. It has also been suggested that NHERF1 may induce 
CFTR dimerization, facilitating CFTR intermolecular interactions, which alter channel 
conformation and activity. However, the role of PDZ-domain proteins in the formation of 
CFTR dimers is controversial26. 
NHERF1 role upon CFTR stabilization involves also interaction with small GTPases 
(guanosine triphosphate hydrolase) of the Rho family. These GTPases, found in all 
eukaryotic organisms, are divided into three subfamilies, grouped according to their 
functional and structural similarity to their three founding members, RhoA, Rac1, and 
Cdc4210. The members of the Rho family are key regulators of actin cytoskeleton 
dynamics, cell polarity and membrane trafficking through their modulation of F-actin 
remodeling10, 29, 30. Consistently, NHERF1 overexpression stimulates the activation of 
endogenous RhoA and RhoA-activated kinase (ROCK), thus leading to reorganization of 
the actin cytoskeleton and stabilization of the multiprotein complex F508del-CFTR–
NHERF1–ezrin–actin at the apical PM31. Therefore, CFTR surface anchoring and retention 
may be a major target pathway to be considered in CF pharmacotherapy10. 
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Figure 1.4: CFTR anchoring at the plasma membrane. Several proteins interact directly or 
indirectly with CFTR, including protein phosphatase-2A (PP2A), Na+/H+ exchanger regulatory 
factor isoform-1 (NHERF1), protein kinase A (PKA) and ezrin, forming a multiprotein complex that 
stabilizes CFTR at the plasma membrane. ERM, ezrin, radixin, moesin binding domain; NBD, 
nucleotide-binding domain; R, regulatory domain
Adapted from 26
. 
 
 
1.5 CFTR function 
CFTR functions mainly as a chloride channel, playing a fundamental role in fluid and 
electrolyte transport across the epithelial cells and regulation of the airway surface liquid 
composition. However, CFTR function is not restricted to being a chloride channel, being 
also permeable to other anions, namely bicarbonate, thus providing an important role as a 
regulator of transmembrane pH gradients32, 33. CFTR is also implicated in the control of 
extracellular reactive oxidative species balance, as a result of glutathione transport34, 35. 
Therefore, because this channel regulates transepithelial salt and water movement, it 
coordinates epithelial hydration and efficient mucociliary clearance. This is also achieved 
through the regulation of other PM channels, namely the epithelial sodium channel 
(ENaC), calcium-activated chloride channels (CaCCs), outwardly rectifying chloride 
channels (ORCCs) and renal outer medullary potassium channel (ROMK)36-39. Contrary to 
other ABC transporters, CFTR is incapable of actively driving ion transport against a 
gradient; instead, it functions as a passive channel that allows bidirectional flow of ions14. 
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CFTR chloride channel gating is tightly regulated by the balance of kinases and 
phosphatases activity within the cell and by the cellular levels of ATP and cAMP. The 
MSDs contribute to the formation of the chloride pore and NBDs bind and hydrolyze ATP 
to regulate the channel gating. Activation of the cAMP-dependent protein kinase A (PKA) 
drives the phosphorylation of multiple serine/threonine residues within the R domain, 
required to channel activation. Finally, protein phosphatases dephosphorylate the R 
domain and return the channel to its quiescent state (Figure 1.5)12.  
 
 
Figure 1.5: Regulation of the CFTR chloride channel opening. Schematic model showing the 
regulation of CFTR through cAMP-dependent phosphorylation of the R domain (RD) and ATP 
binding and hydrolysis at the NBDs. In and Out denote the intra- and extracellular sides of the cell 
membrane. MSD, membrane-spanning domain; NBD, nucleotide-binding domain; P, 
phosphorylation of the R domain; PKA, protein kinase A; PPase, protein phosphatase
40
. 
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This PKA-mediated activation of CFTR requires integrity of the actin cytoskeleton and 
compartmentalized cAMP within the cell41. It has been reported that the cAMP increase 
required for PKA-mediated activation of CFTR must be specifically localized near the 
membrane, in the subcortical compartment31, 41. Additionally, this compartmentalization is 
dependent on the integrity of the subcortical cytoskeleton and on the presence of 
adenylate cyclases (AC; responsible for the production of cAMP) and A-kinase anchoring 
proteins (AKAPs), such as ezrin. AKAPs are scaffold proteins, anchoring PKA, 
phosphatases, phosphodiesterases and other signaling proteins in the vicinity of CFTR. 
The formation of multiple protein macromolecular complexes in subcellular microdomains 
increases the specificity and efficiency of signaling towards CFTR, allowing a cAMP-
dependent control of chloride efflux14, 41-44. Although it is well-established that cAMP plays 
a crucial role in CFTR regulation, PKA is not the only cAMP sensor within the cell. 
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1.6 EPAC – Overview 
Since the discovery that cAMP activates the phosphorylating enzyme PKA, the cAMP 
messenger system has been shown to regulate cAMP production by heteromeric guanine 
nucleotide–binding proteins (G proteins), subsequent binding of cAMP to PKA, and 
consequent phosphorylation of PKA substrates45, 46. cAMP is a second messenger that 
has a role in many physiological processes ranging from the regulation of heart rhythm, 
insulin secretion or neurotransmitter release47, 48. Initially, PKA was considered to be the 
essential effector molecule mediating many of these physiological effects initiated by 
receptors coupled to generation of cAMP45, 46, 49. However, PKA has not been clearly linked 
to all these processes45. A database screen conducted to explain the insensitivity of 
cAMP-induced activation of the small GTPase Rap1 to inhibitors of PKA, in 1998, led to 
the identification of EPAC, an exchange protein directly activated by cAMP (also known as 
cAMP-GEF), heralding the age of signal transduction47, 48, 50. This approach identified 
independently two proteins containing a cyclic nucleotide-binding (CNB) domain: EPAC1 
and EPAC2 (or RAPGEF3 and 4, respectively). Another protein highly homologous to 
EPAC with activity toward Rap, known as REPAC (or RAPGEF5), was later identified; 
however, this protein lacks a cAMP-binding domain51. 
EPAC proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and 
Rap251. Rap is a small Ras-like GTPase that was first identified as a protein that could 
suppress the oncogenic transformation of cells by Ras. It belongs to the Ras superfamily 
of small G proteins, specifically to the Rap subfamily, which cycle between an inactive 
guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-
bound state. Thus, small G-proteins function as simple molecular switches with an inactive 
GDP-bound and active GTP-bound conformation47, 50, 52. GEFs catalyze the exchange of 
GDP for GTP and thereby the activation of the G protein, whereas GTPase-activating 
proteins (GAPs) enhance GTP hydrolysis. Several other GEFs for Rap, in addition to 
EPAC, have been identified. These GEFs connect different inputs to Rap activation and 
are associated to distinct functions of Rap. The most intriguing RapGEF, however, is 
EPAC, because this GEF represents a novel target for cAMP, independent from the 
classical target protein PKA51. Rap, whose activation by cAMP occurs independently of 
PKA, is activated by several extracellular stimuli and is involved in an immense diversity of 
cellular processes such as cell proliferation and adhesion, actin cytoskeleton dynamics, 
cell polarity, exocytosis, membrane protein recycling and cell differentiation50, 54-61. 
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EPAC1 and EPAC2 are present in most tissues, although with different expression levels: 
EPAC1 is highly abundant in blood vessels, skeletal muscles, central nervous system, 
kidney, adipose tissue, ovary and uterus; EPAC2 is mostly expressed in the central 
nervous system, pancreas and adrenal gland45, 50, 62. REPAC is strongly expressed in the 
human brain63. 
 
1.7 EPAC protein and its activation 
EPAC1 and EPAC2 are multidomain proteins that consist of an N-terminal regulatory 
region and a C-terminal catalytic region (Figure 1.6a). The regulatory region has one 
(EPAC1) or two (EPAC2) CNB domains and a DEP (Dishevelled, Egl-10, and Pleckstrin) 
domain. The catalytic region harbors the CDC25-homology domain (CDC25-HD) for 
enzymatically exchange activity, which is stabilized by a Ras exchange motif (REM) 
domain. There is a Ras-association (RA) domain between these domains. The regulatory 
region has an autoinhibitory function that is relieved by binding of cAMP (Figure 1.6b)47, 48, 
51, 64, 65. In the inactive conformation, the CNB domains sterically prevent Rap binding to 
the catalytic site. As already known for EPAC2, an ionic interaction between the C-terminal 
CNB (CNB-B) domain and the CDC25 domain dynamically stabilizes this conformation. 
Upon binding of cAMP, a subtle change within the CNB-B domain allows the regulatory 
region to move away from the catalytic region. This position is stabilized by interactions 
between cAMP, CNB-B and REM domains47, 66, 67. 
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Figure 1.6: Structure of EPAC. (a) Schematic representation of the domain architecture of both 
EPAC proteins. The regulatory region contains one or two CNB (cyclic nucleotide–binding) domains 
and a DEP (Disheveled, Egl-10, and Pleckstrin) domain. The catalytical region harbors the CDC25-
homology domain (CDC25-HD), the Ras exchange motif (REM) domain and a Ras-association (RA) 
domain. (b) Crystal structure model of both inactive and active EPAC2. For simplicity, only the 
catalytic region and the CNB-B domain (indicated with a dotted line in panel a) are shown
47
. 
 
Hormonal stimulation of many heterotrimeric G-protein-coupled receptors frequently 
results in the activation of AC leading to an increase in cAMP levels. cAMP can be then 
degraded by phosphodiesterases (PDE). In the past, the discovery and analysis of cAMP-
mediated events has been greatly facilitated by specific compounds that modulate 
intracellular cAMP levels. The most commonly used ones are forskolin, a natural 
compound that directly activates ACs, and a variety of PDE inhibitors, such as 3-isobutyl-
1-methylxanthine (IBMX), both added to further enhance cAMP levels47, 48, 68. During the 
development of EPAC-selective analogs of cAMP, it was noticed that EPAC proteins lack 
the glutamate residue that, in PKA and cAMP-gated ion channels, interacts with the ribose 
A 
B 
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of cAMP. Taking advantage of this knowledge, 8-pCPT-2’-O-Me-cAMP (also known as 
007) was developed as a selective agonist for EPAC, being ten times more efficient than 
cAMP in activating EPAC1. To increase the relatively low membrane permeability of this 
compound, an acetoxymethyl (AM)-ester was introduced to mask the negatively charged 
phosphate group, originating 007-AM. This modification allows exceptional cell 
permeability being intracellularly removed by esterases to generate 00747, 69-71. Despite 
007-AM also activating EPAC2, it was reported recently that sulfonylurea selectively 
activates EPAC2 isoform, but not the closely related EPAC1, further establishing a new 
class of isoform-selective enzyme activators48, 72. 
 
1.8 Spatial regulation of EPAC 
Although cAMP can rapidly diffuse within the cytosol, it becomes unevenly distributed and 
concentrated in local microdomains. Thus, cAMP-elevating hormones do not induce 
homogenous increases of cAMP within the cell. The molecular basis of this cAMP 
signaling compartmentalization involves its synthesis by membrane-associated AC, 
subsequent diffusion through the cell and local cAMP degradation by PDEs. As a result, 
these cAMP mediators generate cAMP gradients within the cell47, 73. In addition to cAMP 
compartmentalization, cAMP effectors are also spatially regulated by binding to scaffolding 
proteins, as has been previously shown for PKA (section 1.5). AKAPs target PKA to 
distinct subcellular locations and mediate the assembly of large signaling complexes, 
linking PKA to specific cellular functions. In a similar way, EPAC proteins are spatially 
regulated by different anchoring mechanisms47. 
In response to the cAMP-induced conformational change, EPAC1 is targeted to the PM. 
This is essential for the ability of EPAC1 to induce its downstream effectors, like Rap, at 
the PM74. The DEP domain is required for this translocation and it has been shown to 
tether EPAC1 to phosphatydic acid (PA) at the membrane75. EPAC1 is also tethered to the 
PM by an additional mechanism, through phosphorylated (active) ERM scaffolding 
proteins76. Thus, EPAC1 can be recruited to PM by two different pathways: one is through 
PA and is cAMP- and DEP-dependent; the other way is through ERM proteins and is 
cAMP-independent and N-terminal-region-dependent75, 76. Radixin has also been reported 
to bind EPAC1 and PKA simultaneously, bringing these two cAMP sensors together and 
creating a functional cAMP-sensing compartment for efficient signal transduction77. All 
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these data suggest that EPAC1 might co-localize or even interact with CFTR, which 
argues for a possible function of this GEF in CFTR function regulation or membrane 
stability. Additionally, EPAC1 is activated by stimuli that result in increased subcortical 
cAMP, the same stimuli that induce PKA-mediated activation of CFTR, which further 
supports this hypothesis. 
EPAC2 is targeted to the PM after binding to activated Ras proteins, via its RA domain and 
independently of its conformational state78.  
Several other subcellular localizations have been reported for EPAC1, some of which link 
EPAC1 to specific cellular processes (Figure 1.7). Nuclear EPAC1 was found to regulate 
the DNA damage–responsive kinase (DNA-PK) within the nucleus79. EPAC1 is also 
targeted to microtubules, in interphase or mitotic cells, and this interaction is probably 
required for the role of EPAC in microtubule polymerization. EPAC1 has also been 
observed in other localizations that may be associated with distinct functions, such as 
centrosomes, mitochondria, the nuclear pore complex and the apical membrane of renal 
epithelial cells47, 52. The multidomain structure of EPAC indicates that it may have multiple 
binding partners, and indeed numerous interacting proteins have already been described 
for both EPAC1 and EPAC2. Alternative splicing may further add another layer of 
complexity to the spatial regulation of EPAC47. 
 
 
Figure 1.7: Spatial regulation of EPAC1. (a) Spatial regulation of the EPAC1, showing how the 
diverse EPAC1-interacting proteins (blue) affect the localization of this GEF. ERM, Ezrin, Radixin, 
Moesin; MAP1, microtubule-associated protein 1; PDE4D3, phosphodiesterase 4D3; RanBP2, Ran-
binding protein 2
Adapted from 52
. 
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1.9 Biological functions of EPAC 
The major catalytic function of EPAC is the guanine nucleotide exchange of Rap1 and 
Rap2, with EPAC thus controling the Rap-mediated processes downstream of cAMP. 
However, several other GEFs or GAPs can regulate Rap activity and Rap1 and Rap2 
might not mediate all effects of cAMP-EPAC (Figure 1.8). It has been reported that EPAC1 
also activates R-ras, a Ras-like small GTPase implicated in the control of integrin-
mediated cell adhesion. Undoubtedly, the EPAC-selective cAMP analog 007 has helped to 
highlight a role for EPAC and Rap in a wide range of biological processes, ranging from 
exocytosis of insulin in the β-cells of the pancreas to the regulation of calcium currents in 
cardiomyocytes, permeability of the vascular endothelium, ionic transport across intestinal 
cells and tissue fibrosis. Most of these processes are also modulated by signaling via the 
cAMP effector PKA, proving the interconnectivity between both cAMP pathways47, 48, 80-83. 
Indeed, both cAMP targets are often associated with the same biological process, in which 
they fulfill either opposite or synergistic effects. This dual control may enhance the 
dynamic range of cAMP signaling, as PKA-mediated events are proposed to occur at 
much lower cAMP levels than the activation of EPAC84. For increased complexity, the 
spatial localization of EPAC is also a crucial determinant of its function48. Thus, it is 
anticipated that the study of EPAC as a cAMP-signaling mediator is a starting field with a 
lot more to be discovered, in the same way that cAMP has been a major hit of research 
since its discovery more than 50 years ago. 
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Figure 1.8: Interconnectivity between the EPAC- and PKA-signaling pathway. After stimulation of a 
receptor (R) coupled to a stimulatory G protein (Gs), adenylate cyclase (AC) is activated, promoting 
cAMP synthesis and consequent activation of both EPAC and PKA. Both proteins are involved in 
the regulation of cell adhesion, cell–cell junction formation, secretion and ion channels. Inhibitory G 
proteins may also inhibit AC activity. PDE, Phosphodiesterase; GEF, guanine-nucleotide-exchange 
factors; GAP, GTPase-activating protein
48
. 
 
Although a potential connection between CFTR and EPAC has never been reported, this 
cAMP effector is involved, as already mentioned, in the regulation of cell-to-cell and cell-
matrix adhesion, cytoskeleton rearrangements and cell polarization, processes that affect 
CFTR regulation41, 85, 86. Thus, more detailed knowledge about a potential relationship 
between CFTR and EPAC is needed, as EPAC may be a new link between CFTR and 
cAMP.
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1.10 Objectives 
Here, we proposed to study the role of a novel cAMP signalling pathway in the regulation 
of CFTR at the plasma membrane in order to better understand the mechanisms by which 
the protein is anchored at its cellular location and ultimately how can this be modulated for 
the benefit of CF patients.  
Specifically, the aim of the present work is to study the interaction between CFTR and 
EPAC1, the predominant isoform of EPAC in cAMP signaling, and to evaluate the impact 
of this cAMP effector on CFTR biogenesis, trafficking and PM anchoring. In order to 
achieve this goal, we propose to: 
1- Validate 007-AM as a specific cAMP analogue for EPAC in Cystic Fibrosis 
Bronchial Epithelial cells (CFBE) by fluorescence resonance energy transfer 
(FRET) and co-immunoprecipitation (co-IP); 
2- Validate cAMP-induced translocation of EPAC in CFBE cells by confocal live-cell 
imaging and cell fractionation; 
3- Evaluate co-localization and interaction between CFTR and EPAC1 (and the effect 
of 007-AM) by confocal live-cell imaging and co-IP; 
4- Characterize the molecular linkers involved in the CFTR and EPAC1 interaction 
and the role of PDZ binding domain on CFTR-EPAC1 interaction; 
5- Assess the effect of EPAC1 on CFTR PM stability using endocytosis and 
biotinylation assays; 
6- Assess the dependence of EPAC-induced cell adhesion dependence on the 
expression of CFTR. 
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2. Materials and Methods 
2.1 Molecular Biology 
2.1.1 Plasmid vectors and siRNAs 
All plasmids and siRNAs (small interfering RNA) used in this work are listed on the 
following tables (Table 2.1 and 2.2, respectively). Maps for all vectors are available in 
Appendices Plasmid maps. 
 
 
Table 2.1: List of plasmids used and their description. 
Plasmid Name 
Vector (antibiotic 
resistance) 
Description 
pEGFP-EPAC1 
pEGFP-C2 
(kanamycin) 
GFP-EPAC1 fusion protein tagged with GFP 
at the N-terminus of EPAC1 
pEGFP-C2 
Destination vector for expression of proteins 
with a GFP tag at the N-terminus (used as 
control) 
pcDNA3.1-CFTR 
pcDNA3.1 
(ampicillin) 
WT or ∆TRL (1478-1480) CFTR 
pmCherry-C2-
CFTR-FLAG 
pmCherry-C1 
(kanamycin) 
mCherry- CFTR fusion protein with the 
mCherry tag at the N-terminus containing a 
FLAG at the forth extracellular loop of WT- or 
F508del- CFTR 
Raichu-Rap1 
pCAGGS 
(ampicillin) 
FRET sensor (EYFP-ECFP) that responds to 
EPAC activity87 (section 2.4) 
AKAR4 
pcDNA3.1+ 
(ampicillin) 
FRET sensor (EYFP-ECFP) that responds to 
PKA activity88 (section 2.4) 
camps pcDNA3 (ampicillin) 
FRET sensor (EYFP-ECFP) that responds to 
cAMP levels89 (section 2.4) 
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Table 2.2: List of siRNA used. 
siRNA Name Brand (Reference) 
Silencer® Select Negative Control No. 2 siRNA Life Technologies (4390846) 
Silencer® Select siRNA RAPGEF3 Life Technologies (4392420) 
siGENOME SMART pool non-targeting siRNA Thermo Scientific (D-001206-13) 
siGENOME SMART pool human EZR Thermo Scientific (EG:7430) 
siGENOME SMART pool human SLC9A3R1 Thermo Scientific (EG:9368) 
 
2.1.2 Transformation of competent bacteria 
The bacterial strains used for cloning and DNA amplification were: One Shot TOP10 
(Invitrogen) or 2); XL1-Blue competent cells (Stratagene). Preparation of competent 
bacteria was done in-house according to the technique described by Hanrahan90.  
Bacteria were transformed by incubating a 200µL aliquot of competent bacteria with DNA 
(at least, 100ng of ligation products or 5ng of purified plasmids) for 30 min in ice. 
Afterwards, the mixture was submitted to heat-shock (90 sec at 42ºC), incubated 2 min on 
ice followed by incubation in LB media without antibiotic for 45 min at 37ºC at 220rpm, in 
order to allow antibiotic resistance to be expressed. After pelleting the bacteria (3000g for 
5 min), the supernatant was discarded and the pellet was resuspended in the remaining 
medium. This suspension was then plated into LB-agar supplemented with appropriate 
concentration of the selected antibiotic and plates were incubated overnight at 37ºC. 
Transformed bacterial colonies were then grown in LB medium supplemented with the 
appropriate antibiotic and plasmid DNA was extracted. Clones were stored in liquid LB 
medium supplemented with 15% (w/v) glycerol (Sigma-Aldrich) at -20ºC. 
 
 
2.1.3 DNA extraction and quantification 
Plasmid DNA was purified, at small or large scale, with QIAGENMiniprep kit (QIAGEN) or 
QIAGENMaxiprep kit (QIAGEN), respectively, accordingly with manufacturer’s guidelines. 
DNA concentration was determined by measurement of the absorbance at 260nm using a 
Nanodrop 2000 spectrophotometer (Thermo Scientific) and its purity was evaluated by 
assessment of the A260/A280 ratio. Only DNA with a ratio above 1.8 was considered pure 
enough for further use. 
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2.1.4 Mutagenesis  
The TRL deletion was performed on pcDNA3.1-WT-CFTR using the KOD Hot Start DNA 
Polymerase (Novagene) with a pair of complementary custom designed mutagenic 
primers (Thermo Electron Corporation): delTRL_FW (forward primer, sequence 5’- 
GAAGAGGTGCAAGATTAGAGAGCAGCATAAATG-3’) and delTRL_REV (reverse primer, 
sequence 5’-CATTTATGCTGCTCTCTAATCTTGCACCTCTTC-3’). Primers were designed 
with the software BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html). The PCR 
program used for the mutagenesis reaction is displayed in the following table. 
 
Table 2.3: PCR program for the mutagenesis reaction. 
Temperature (ºC) Time Number of cycles 
95 2min 
18 
95 20s 
47 20seg 
70 5min 
 
 
After confirming the DNA amplification by agarose gel electrophoresis, the PCR products 
were incubated for 1h with DpnI (Invitrogen), a restriction enzyme that specifically 
hydrolyzes methylated and semi-methylated DNA, thus degrading the non-amplified 
template DNA. After bacteria transformation (section 2.1.2) and DNA extraction (section 
2.1.3), the presence of the mutation was confirmed by DNA sequencing (section 2.1.5). 
 
 
2.1.5 DNA sequencing 
The sequencing reactions were outsourced to StabVida. Primers used for CFTR and 
EPAC plasmids are listed below (Table 2.4). All sequencing primers were obtained 
through StabVida. The resulting sequences were analyzed using the BioEdit software by 
comparison with a reference sequence. 
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Table 2.4: Primers used for sequencing. 
Primers 
For CFTR plasmids 5’ – 3’ 
AC1L Reverse GAAACCAAGTCCACAGAAGGC 
CMV 
Forward 
CGCAAATGGGCGGTAGGCGTG 
Ex5F CTCCTTTCCAACAACCTGAAC 
B3R AATGTAACAGCCTTCTGGGAG 
C2R AGCAGTATACAAAGATGCTG 
D1R GACAACAGCATCCACACGAA 
E1R AGATTCTCCAAAGATATAGC 
Ex18F AACTCCAGCATAGATGTGG 
Ex22F AGCAGTTGATGTGCTTGGC 
 
For EPAC plasmid 5’ – 3’ 
CMV 
Forward 
CGCAAATGGGCGGTAGGCGTG 
EGFP CATGGTCCTGCTGGAGTTCGTG 
RapGEF3a1 TACGCATTCCTCTACCGTAAG 
RapGEF3b2 AGCCGAAGCTGCATTTCTG 
RapGEF3b3 AAGGAAGTAGTTCTGCCTGG 
RapGEF3 Reverse AGATTCCCACAACTTGGCTC 
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2.2 Cell Culture  
Cells were cultured in the appropriate medium in plastic flasks or plates, in an incubator 
with a humidified atmosphere of 5% CO2 at 37ºC. For cell detachment from the plastic 
surface, cells were washed with in PBS and then incubated with trypsin (Life 
Technologies). Cell lines were stored frozen at -80ºC or in liquid nitrogen in 40% (v/v) of 
the appropriated cell medium, 50% (v/v) FBS and 10% (v/v) DMSO (Sigma-Aldrich). To 
minimize cell damage, freezing was performed in a way that allows a cooling speed 
around 1ºC/min. After thawing, cells were washed and seeded with the indicated medium 
for each cell line (see below). To eradicate/prevent mycoplasma contamination, cells were 
treated occasionally with Myco4 (AppliChem). To assess cell contamination, a PCR test 
for Mycoplasma was performed. 
 
 
2.2.1 Cell types 
2.2.1.1 CFBE cells 
Cystic Fibrosis Bronchial Epithelial (CFBE41o-) cells91, from now on simply referred as 
CFBE, stably overexpressing either WT- or F508del-CFTR92 or without expressing CFTR 
(parental CFBE) were cultured in Eagle’s minimal essential medium (EMEM; Life 
Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies), 2mM 
L-glutamine (Invitrogen). When appropriate/needed, medium was also supplemented with 
an antibiotic mixture of penicillin (Pen; 100U/mL; Life Technologies) and streptomycin 
(Strep; 100µg/mL; Life Technologies) and with puromycin (2.5µg/mL; Life Technologies). 
 
 
2.2.1.2 Calu3 cells 
Non-transduced Calu393 cells (Calu3-WT) or expressing a control (Calu3 shControl), Ezrin 
(Calu3 shEzrin) or NHERF1 shRNA (Calu3 shNHERF1) were generated in this work 
(section 2.2.4) and used for further analysis. Cells were cultured in DMEM-F12 (Lonza) 
media supplemented with 10% FBS and with or without puromycin (5µg/mL). 
  
Chapter II 
26 
 
2.2.1.3 A549 cells 
A549 cells overexpressing mCherry-WT- or mCherry-F508del-CFTR94 under control of a 
tet-on promoter were cultured in DMEM (Lonza) media supplemented with 10% FBS and 
puromycin (2.5µg/mL). CFTR expression was induced with 10 µg/mL of doxycycline and 
1mM of sodium butyrate for 24h. 
 
2.2.1.4 HEK293 cells 
Human Embryonic Kidney (HEK293) cells95 were cultured in DMEM media supplemented 
with 10% FBS. 
 
 
2.2.3 Transfections  
Cells were transiently transfected with plasmid DNA or siRNA (section 2.1.1) using 
Lipofectamine2000 (Life Technologies), a cationic liposome formulation that forms DNA 
complexes able to fuse with cell membrane, according to the manufacture’s guidelines96.  
Usually, for one 6 well-plate, 750µL of OptiMEM (Life Technologies) were mixed with 36µL 
of Lipofectamine and other 750µL of OptiMEM were mixed with 12µg of plasmid DNA or 
1µL of 20µM siRNA and incubated at RT (room temperature) for 5min. After that, the 
second mixture was added to the first one and incubated 30min at RT. 250µL of this final 
mixture was added to each well with 60-90% confluent cultured cells. 
Medium was changed after 6h and all experiments were done 24 to 48h after transfection. 
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2.2.4 Lentivirus infection 
2.2.4.1 Lentivirus production 
HEK293 cells were transiently transfected with a mixture of the packaging (pCMV-
dR8.74psPAX2), envelop (pMD2.G) and hairpin-pLKO.1 vector (Empty vector control, 
SHC001; NHERF1, SHCLND SLC9A3R1; Ezrin, SHCLND EZR; Sigma-Aldrich) plasmids 
using X-tremeGENE9 DNA transfection reagent (LifeScience), according to the 
manufacturer’s guidelines, and incubated at 37ºC. Because lentivirus start to appear in the 
media supernatant ~22h post-transfection, 18h after incubation at 37ºC, the transfection 
reagent medium was removed and replaced with high-BSA growth media (DMEM 
supplemented with 10%iFBS (inactivated FBS), 1.1g/100mL BSA (Bovine serum albumin) 
and 1x Pen/Strep). The next day, the media was harvested and stored at -20ºC. The cells 
were incubated again with high-BSA growth media and the medium was harvested one 
last time 24h later. 
 
 
2.2.4.2 Production of a stable cell line 
After washing 70% confluent Calu3-WT cells with Hank's Balanced Salt Solution (HBSS; 
Life Technologies), EMEM medium supplemented with 10% (v/v) FBS, polybrene (8µg/mL) 
and 5-20% (v/v) lentivirus-containing medium (section 2.2.4.1) was added to the cells. 
After centrifugation (2200rpm) at 37ºC for 30min, the cell plates were incubated at 37ºC for 
24h. The medium was then replaced by EMEM supplemented with 10% (v/v) FBS and 
puromycin (5µg/mL), which allows the selection of cells that were efficiently infected. This 
medium change was repeated for, at least, 5 consecutive days. 
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2.3 Biochemical Analysis 
2.3.1 Cell lysis and total protein quantification 
For protein extraction, cells were washed 3 times with cold PBS and lysed with sample 
buffer (1.5% (w/v) SDS; 5% (v/v) glycerol; 0.01% (w/v) bromophenol blue; 0.05mM 
dithiotreitol; 0.095M Tris pH 6.8). DNA was sheared by enzymatic action of 5-25U/mL of 
benzonase (Sigma-Aldrich) in the presence of MgCl2 2.5mM. 
Total protein quantification was performed using Bradford method. 1mL of Bradford 
reagent (Sigma Aldrich) was added to 2µL or 5µL of sample. A standard curve was 
performed by adding 1mL of Bradford solution to increasing concentrations of BSA (Sigma 
Aldrich) standards. Afterwards, the absorbance was measure at 595nm and data analysis 
was performed. 
 
2.3.2 Western blot 
Protein extracts were separated by SDS-polyacrylamide gel electrophoresis (PAGE) on 
7.5, 8, 10 or 12.5%T (w/v) separating and 4%T stacking gels at 100-150 V. Subsequently, 
proteins were transfered onto Immobilon polivinylidene difluoride (PVDF) membranes 
(Millipore) at 400 mA for 1.5h. After blocking with 5 % (w/v) skimmed milk in phosphate-
buffered saline (PBS: NaCl 137mM; KCl 2.7mM; KH2PO4 1.5mM; Na2HPO4 6.5mM, pH 
7.4) containing 0.1% (v/v)-Tween (PBS-T) or Tris-buffered saline with 0.5% Tween 20 
(TBS-T; Alfa Aesar) for 1h at RT, membranes were incubated overnight with primary 
antibodies (Table 2.5) at 4ºC. After three 10 min washes with PBS-T/TBS-T, the 
membranes were incubated 1h at RT with horseradish peroxidase-conjugated secondary 
antibody (see antibodies on Table 2.5) and washed as above. All antibodies were diluted 
in blocking solution. Chemiluminescent detection was performed using: Chemidoc XRS+ 
analyser (BioRad) and the signal was developed with the ImmunStar Western C 
Chemiluminescence kit (BioRad) or using Compact X4 Automatic Processor (Xograph) 
and the signal was developed using ECL Western Blotting Substrate (Thermo Scientific). 
The quantification of band volume was performed using the Image Lab software (BioRad) 
or ImageJ (http://imagej.nih.gov/ij/). In order to re-incubate with another primary antibody, 
the membranes were washed at least 5 times for 10 min with PBS-T or TBS-T, or washed 
1h with PLUS Western Blot Stripping Buffer (46430, Thermo Scientific). After this washing 
step, the membranes were blocked again for 1h at RT.  
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Table 2.5: List of primary and secondary antibodies used. 
Antibody Antigen Reference (Brand) 
Application 
(Dilution) 
Primary 
α-tubulin T5168 (Sigma Aldrich) WB (1:2000) 
β-tubulin sc-9104 (Santa Cruz Biotechnology) WB (1:1000) 
Calnexin 610523 (BD Biosciences) WB (1:1000) 
CFTR (NBD2) 596 (Cystic Fibrosis Foundation) 
WB (1:3000), 
IP (1:1000) 
EPAC1 
ARP52140_P050 (Aviva Systems 
Biology) 
WB (1:1000), 
IP (1:1000) 
Ezrin 610602 (BD Biosciences) WB (1:1000) 
GAPDH sc-166574 (Santa Cruz Biotechnology) WB (1:1000) 
GFP sc-9996 (Santa Cruz Biotechnology) WB (1:1000) 
NHERF1 611160 (BD Biosciences) WB (1:1000) 
Rap1A sc-1482 (Santa Cruz Biotechnology) WB (1:200) 
TNF-R1 Sc-8436 (Santa Cruz Biotechnology) WB (1:1000) 
Secundary  
Mouse IgG, HRP-
conjugated 
W4018 (Promega)/1703516 (BioRad) WB (1:3000) 
Rabbit IgG, HRP-
conjugated 
W4028 (Promega)/ 1706515 (BioRad) WB (1:3000) 
 
 
2.3.3 Immunoprecipitation 
Cells were grown in P60/P100 plates until confluence was reached and then lysed with 
0.5/1mL PD buffer (50mM Tris-HCl, 0.1M NaCl, 1% (v/v) NP40 (Roche), 10% (v/v) 
glycerol, pH 7.5 supplemented with a 1x Complete protease inhibitor cocktail (Roche) at 
4ºC and collected with a cell scraper. After that, cell membranes and debris were pelleted 
by centrifugation at 10,000rpm for 5min at 4ºC and the supernatant was pre-cleared 
through incubation at 4 ºC for 2h with 40µL of Protein-G agarose beads (Invitrogen). The 
beads were pelleted by centrifugation for 1min at 10,000rpm followed by overnight 
incubation of the supernatant with the appropriate antibody (see antibodies on Table 2.5) 
at 4ºC. For mCherry pull-down, anti-RFP antibody-linked beads (RFP-Trap_A sta-20; 
Chromotek) or untagged beads (bab-20; Chromotek), as a control, were used. In this case, 
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no pre-clearing step was performed. The beads were pelleted by centrifugation for 1min at 
10,000rpm, washed 3x with wash buffer (Tris-HCl 0.1M, NaCl 0.3M, Triton X-100 1% (v/v), 
pH 7.5) followed by elution with 1x sample buffer and spin-down. For certain samples, a 5 
min incubation at 90ºC was performed. The immunoprecipitate was loaded and separated 
on SDS-PAGE gels and analyzed by Western Blot (section 2.3.2). 
 
2.3.4 Rap1A activity assay 
The active fraction of Rap was purified using a pull-down assay, as described97. This 
assay exploits the selective interaction of the Rap-binding domain (RBD) of RalGDS with 
the active, GTP-bound form of Rap. This domain was expressed tagged with glutathione 
S-transferase (GST), which strongly binds to glutathione-coupled agarose beads. These 
beads allow to selectively pull-down active Rap from cell extracts (Figure 2.1). 
 
 
Figure 2.1: Schematic representation of the Rap1A activity assay. 
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For the beads preparation, bacteria transformed with pGEX-RalGDS-RBDGST (a kind gift 
from Dr.David Altschuler, University of Pittsburgh School of Medicine) were grown in LB 
medium. After reaching an OD600 of 0.6, the expression of RalGDS-RBD-GST fusion 
protein was induced with IPTG 1mM (Isopropyl β-D-1-thiogalactopyranoside; NZYTech) for 
4h, followed by a centrifugation to collect the bacteria. These were resuspended in PBS 
containing 1x Complete protease inhibitor cocktail (Roche) and sonicated 10x 10 cycles of 
0.7s. Proteins were solubilized with 1% (v/v) Triton X-100 (GE Healthcare) for 30min at 
4ºC, centrifuged 10min at 10000 g and incubated with glutathione agarose beads (Thermo 
Scientific) for 1-2 hours at 4ºC. Finally, the beads were diluted 1:1 in PBS and a 50% slurry 
was added 1:1 to glycerol and stored at - 20ºC. 
The expression of the recombinant protein, after induction with IPTG, was monitored by 
running aliquots of bacterial lysates (taken before and after the addition of IPTG) in a SDS-
PAGE gel. The gel staining with Coomassie Blue showed a robust expression after adding 
IPTG (Figure 2 Appendices). GST-RalGDS-RBD-coupled beads were also confirmed in a 
SDS-PAGE, confirming that the protein was effectively captured (Figure 4 Appendices). 
 
For the pull-down assay, cells were lysed on ice in Rap1A lysis buffer (25mM Tris-HCl, 1% 
(v/v) NP-40, 5mM MgCl2, 150mM NaCl, 0.1mM DTT, 5% (v/v) glycerol, Complete 
protease inhibitor cocktail, pH 7.5) for 15min. Lysates were centrifuged 10,000g for 10min 
at 4ºC and the supernatant was incubated with glutathione agarose beads coupled to 
GST-RalGDS for 2 hour at 4ºC. For Western Blot analysis, beads were washed and 
resuspended in 1x sample buffer for Western Blot analysis. 
 
 
2.3.5 Biotinylation assay 
Cells were grown in P100 plates until confluence was reached and incubated at 4ºC with 
NHS S-S Biotin buffer (0,1mg biotin (Pierce)/1 mL PBS with 1mM MgCl2, 0.1mM CaCl2, pH 
8.2) for 30 min. Cells were lysed with 1.5mL of BL buffer (25mM HEPES, 1% (v/v) Triton 
X-100, 10% (v/v) glycerol, supplemented with a 1x Complete protease inhibitor cocktail 
(Roche), pH 8.2) and collected with a cell scraper. Cell membranes and debris were 
pelleted by centrifugation at 10,000rpm for 10min at 4ºC and, after pre-clearing, the 
supernatant was incubated at 4ºC overnight with streptavidin beads. The beads were 
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pelleted, washed 1x with BL buffer and 2x with PBS and the samples were then analyzed 
by Western Blot. 
 
2.3.6 Endocytosis assay 
Cells were grown in P100 plates until confluence was reached and incubated at 4ºC with 
NHS S-S Biotin buffer (0,1mg biotin (Pierce)/1 mL PBS 1mM MgCl2 0.1mM CaCl2 pH 8.2) 
for 30min. Endocytosis was promoted by placing the cells at 37 and terminated by 
returning them to 4ºC. Cells were incubated 5 times with GSH solution (75mM NaCl, 1mM 
MgCl2, 0.1mM CaCl2, 50mM GSH (Sigma), 80mM NaOH, 10% fetal bovine serum, pH 8.6) 
for 15min at 4ºC, lysed with 1.5mL of BL buffer (25mM HEPES, 1% (v/v) Triton X-100, 
10% (v/v) glycerol, supplemented with a 1x Complete protease inhibitor cocktail (Roche), 
pH 8.2) and collected with a cell scraper. Cell membranes and debris were pelleted by 
centrifugation at 10,000rpm for 10min at 4ºC and, after pre-clearing, the supernatant was 
incubated at 4ºC overnight with streptavidin beads. The beads were pelleted, washed 1x 
with BL buffer and 2x with PBS and the samples were then analyzed by Western Blot. 
 
2.3.7 Cell fractionation 
Cells were grown in P100 plates until 75% confluence was reached, washed 2x with PBS, 
lysed with 0.5 mL of fractionation buffer (205mM sucrose, 20mM HEPES, 10mM KCl, 
1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1mM DTT, supplemented with a 1x Complete 
protease inhibitor cocktail (Roche), pH 7.4) and collected with a cell scraper at 4ºC. Cell 
lysate was incubated in a rocker at 4ºC for 30min and centrifuged at 720g for 5min at 4ºC. 
Supernatant was transferred to a new tube. Pellet was washed with 0.5mL of fractionation 
buffer and centrifuged again at 720g for 10min at 4ºC. Pellet was resuspended in nuclear 
buffer (fractionation buffer with 10% (v/v) glycerol and 0.1% (v/v) SDS added) – this is the 
membrane fraction (includes plasma membrane and other intracellular membranes). The 
supernatant was ultracentrifuged at 100,000g at 4ºC for 1h. The new supernatant is the 
cytosolic fraction and the pellet was discarded. All samples were analyzed by Western 
Blot.  
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2.4 Live cell imaging 
2.4.1 Measurements of cAMP levels and PKA or EPAC activity by fluorescence resonance 
energy transfer (FRET) 
Sensitized emission FRET measurements were performed as already described41, 98. For 
this purpose, the fluorescence emission of the acceptor that results from the radiation-free 
energy transfer of an excited donor molecule is measured. For these experiments, cAMP 
sensor (camps), AKAR4 (A-kinase activity reporter 4) or Raichu-Rap1 FRET sensors were 
used. 
 
- In camps, which is a EPAC-based FRET sensor, the cyclic nucleotide–binding domain of 
EPAC is sandwiched by yellow fluorescent protein (YFP) and cyan fluorescent protein 
(CFP)89, 99-101. The binding of cAMP generates a conformational change, moving apart the 
two fluorophores, thereby decreasing FRET between these two. 
Changes in cAMP concentration using camps were monitored by measuring YFP (545 
nm)/CFP (480 nm) fluorescence emission values upon excitation of the transfected cells at 
430 nm (Figure 2.2). 
 
 
 
Figure 2.2: Schematic representation of camps bound or not to cAMP. The binding of cAMP to 
the cyclic nucleotide–binding domain induces a conformational change that abolishes FRET 
between YFP and CFP
101
. 
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- In AKAR4, a PKA substrate sequence is inserted between the cerulean and venus FRET 
pair100, 102. The phosphorylation of this sensor generates a conformational change, which 
promotes the approaching of these two fluorophores and the increase of FRET signal. 
PKA-mediated phosphorylation using AKAR4 was monitored by measuring venus (545 
nm)/cerulean (480 nm) fluorescence emission values upon excitation of the transfected 
cells at 430 nm (the principle is illustrated for the equivalent AKAR1 in Figure 2.3). 
 
Figure 2.3: Schematic representation of AKAR4 phosphorylated or not phosphorylated. The 
phosphorylation of the domain with a PKA phosphorylation site induces a conformational change 
that allows FRET between venus and cerulean
Adapted from 88
. 
 
 
- There are so far no genetically encodable probes for EPAC activation that are able to 
measure the percentage of endogenous active EPAC. However, since the major output of 
EPAC activation is Rap activation, Raichu-Rap FRET sensor of Rap activity was used as 
an indirect reporter of EPAC activation. In this FRET sensor, the Rap1 sequence is 
between YFP and CFP fluorophores87. The binding of GTP to this FRET sensor, promoted 
by EPAC, generates a conformational change, thereby increasing FRET between the two 
fluorophores. 
EPAC-mediated Rap activation (exchange of GDP by GTP) using the Raichu-Rap FRET 
sensor was monitored by measuring YFP (545 nm)/CFP (480 nm) fluorescence emission 
values upon excitation of the transfected cells at 430 nm (Figure 2.4). 
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Figure 2.4: Schematic representation of Raichu-Rap bound to GDP or GTP. GTP binding, 
promoted by EPAC, induces a conformational change that allows FRET between YFP and 
CFP
Adapted from
 
87
. 
 
FRET imaging experiments were performed 24-48 hours after transfection. Cells were 
maintained at RT or at ~34ºC in Dulbecco's Phosphate-Buffered Saline (DPBS; Life 
Technologies) and imaged on an inverted microscope (Olympus IX81) using a PlanApoN, 
60X, NA 1.42 oil immersion objective, 0.17/FN 26.5 (Olympus, UK). The microscope was 
equipped with an ORCA-AG CCD camera (C4772-80- 12AG, Hamamatsu Photonics, UK), 
White and 505nm light-emitting diode (LED; Cairn Research) and a beam-splitter optical 
device (Dual-view simultaneous imaging system, DV2 mag biosystem, Photometrics, ET-
04-EM). The FRET filter settings used throughout were: CFP excitation filter ET436/20x, 
dichroic mirror 455DCLP (all from Chroma Technology) in the microscope filter cube; 
dichroic mirror 505DCLP, YFP emission filter 545nm, CFP emission filter 480nm (Chroma 
Technology) in the beam splitter. Images were acquired using MetaFluor or MetaMorph 
software (Molecular Devices) and processed using ImageJ. FRET changes were 
measured as changes in the background-subtracted 545/480 nm fluorescence emission 
intensity on excitation at 430 nm and expressed as R/R0, where R is the ratio at time t and 
R0 is the ratio at time = 0 s. Values are expressed as the mean ± SEM. 
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2.4.2 Translocation of EPAC1 and co-localization studies 
Fluorescence imaging was performed 24-48 hours after co-transfection of CFBE or Calu3 
cells with plasmids encoding for GFP-EPAC1 and mCherry-FLAG-CFTR. Cells were 
maintained at RT in Dulbecco's PBS (DPBS; Life Technologies) and imaged on an 
Fluoview FV1000 microscope, which is an inverted IX81 confocal system (Olympus), using 
a 60X, NA 1.35 oil immersion UPlanSApo objective (Olympus). The microscope was 
equipped with a Becker and Hickl FLIM system and with fluorescence filters suitable for 
UV and green or red dyes. Images were acquired using FluoView viewer software (FV10-
ASW software, Olympus) and processed using ImageJ. This confocal fluorescence 
microscope was used to assess the intracellular localization of EPAC1 and CFTR in live 
cells in the absence or presence of 007-AM. The localization of these two proteins was 
monitored and the extent of overlap between the two was quantified using Pearson’s 
correlation coefficient (ImageJ, JACoP plugin)103-106. Briefly, this coefficient describes the 
correlation of the intensity distribution between two channels. Since no threshold needs to 
be defined, no human factor can be introduced during image analysis. This is the main 
reason why Pearson’s coefficient was used instead of others coefficients to estimate co-
localization, such as Manders coefficient or other overlap coefficients. The overlap 
between the images of both proteins was performed using ImageJ software. For 
fluorescence pixel intensity quantification in a specific region of interest (for example, 
plasma membrane), MetaFluor software (Molecular Devices) was used. 
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2.5 Functional Analysis 
2.5.1 Adhesion assay 
The adhesion assay was performed as previously described107. 96-well plates were coated 
overnight with fibronectin coating solution (LHC basal medium (Life Technologies), 
0.1mg/mL BSA (Life Technologies), 29µg/mL bovine collagen I (BD Laboratories, 40231) 
and 10µg/mL human fibronectin (BD Laboratories)). CFBE WT- and F508del-CFTR were 
grown on P100 plates until they reach 80/90% of confluence. At this point, cells were 
incubated with 1µM 007-AM or 5µM ESI-09, an EPAC specific inhibitor (or DMSO as a 
control) and after 2 hours were trypsinized. CFBE cells were resuspended in EMEM 
supplemented with 1µM 007-AM/5µM ESI-09 (or the same volume of DMSO as a control) 
and 0.2 µg/mL of Hoechst 33342 (nucleic acid stain; Life Technologies, H1399) and 
seeded into a fibronectin pre-coated 96 well-plate at a density of 5x104 cells per well. Cells 
were allowed to attach for 30, 60 or 180min and then non-adherent and loosely attached 
cells were removed by washing the wells 3x with 100 µL aliquots of PBS while gently 
shaking the plate. Washes were performed in order to avoid directly affecting the cell 
adhesion. After the final wash, 200µL of EMEM was added to each well. Fluorescence 
intensity (If) at 465nm was measured using a plate reader (Tecan Infinite F200 PRO) 
before and after the washing step. The results are expressed as a percentage of adherent 
cells (ratio between If after washes/ If before washes). For each 96-well plate, a standard 
curve was made to ensure that there was a linear relationship between If and number of 
cells (Figure 5 Appendices). 
 
 
 
2.6 Statistical Analysis  
Data are presented as a mean standard error of the mean (SEM), as indicated in figure 
legends. Data were analyzed using student’s t-test, with p<0.05 accepted as the level of 
statistical significance. 
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3. Results 
3.1 Effect of 007-AM treatment on EPAC1 
The main aim of this work was to assess if EPAC1 and CFTR interact and the influence of 
this cAMP-effector on CFTR biogenesis, trafficking, and PM anchoring. This will allow an 
improved knowledge regarding the relationship between this channel and EPAC1. To 
answer this question, we proposed to use epithelial cells from the respiratory tract. CFBE 
cells were originally isolated from the bronchial epithelium of CF patients and 
immortalized. This cell line (called parental CFBE) has no endogenous expression of 
CFTR and was later transduced with either WT- or F508del-CFTR. These variants allow 
the study of pathways related to CF. Additionally, Calu3 or A549 cells were also used 
because, being lung adenocarcinoma cells, they are also considered as a good model to 
study features of the airway cells. 
The first step was to evaluate the effect of 007-AM, an EPAC specific agonist, on EPAC 
tertiary structure, sub-cellular localization and activity. To prove the selectivity of 007-AM 
to EPAC, a FRET approach (sensitized emission FRET) was chosen using two different 
cAMP-sensors: one based on EPAC (camps) and the other based on a PKA substrate 
(AKAR4) (described in section 2.4.1). Hereupon, both sensors should respond to a 
forskolin (Frsk) treatment while only camps should respond to a 007-AM treatment. We 
chose to use a final concentration of 1µM 007-AM because it has been already reported to 
promote maximum activation of EPAC in A431 and HUVECs cells, being the concentration 
mostly used in the literature76, 108-110. After doing a Frsk standard curve for both sensors, a 
range of Frsk concentrations between 10 and 25µM was chosen (Figure 1 Appendices). 
Thus, cells were initially treated with 1µM 007-AM followed by increasing concentrations of 
Frsk until saturating conditions (Figure 3.1). 
  
Chapter III 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: FRET analysis of cAMP levels and PKA activity in CFBE cells. Analysis of the (A) 
PKA activity-sensor AKAR4 and the (B) cAMP-sensor based on EPAC (camps) upon stimulation 
with 1 µM 007-AM followed by increasing concentrations of Frsk. 25uM Frsk + 100uMIBMX 
represents a saturation condition where adenylate cyclases are fully activated and PDEs are 
inhibited, leading to higher levels of cAMP. H89, a selective PKA inhibitor, was used to show that 
the FRET change is due to a change in PKA activity. FRET change is the normalized 545nm/408nm 
value calculated at each acquisition time point. The three lanes of each plot represent 3 different 
and independent cells. (C) Summary of all experiments performed in A and B, showing the 
percentage of 007-AM-induced FRET change compared to the maximum FRET change for both 
sensors. Data represent means ± SEM. n = 30/19 (AKAR4/camps). 
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As expected, 007-AM induced a high percentage of FRET change for camps while only a 
small FRET change was observed for AKAR4. To decreased this minor effect of 007-AM 
on PKA, a lower concentration of this compound should have been used. Nevertheless, 
this result indicates that 007-AM is an EPAC specific agonist in CFBE cells. However, we 
must have in consideration that AKAR4 measures PKA activity while camps, although it is 
an EPAC-based FRET sensor, measures cAMP levels or EPAC conformational change 
and not endogenous EPAC activity. This will be assessed later (Figure 3.3). 
After confirming the effect of 007-AM on PKA and EPAC activation, the effect of this cAMP 
analogue on EPAC1 localization was assessed by fluorescence confocal microscopy. For  
this, CFBE parental cells or stably expressing WT- or F508del-CFTR were transfected with 
GFP-EPAC1. HEK293 cells were used as a control because EPAC1 translocation to the 
PM after 007-AM treatment has been already reported in these cells76, 108, 109 (Figure 3.2). 
To complement these results, a Western Blot was performed after cell fractionation to 
assess the sub-cellular localization of endogenous EPAC1. 
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Figure 3.2: Analysis of EPAC1 localization after treatment with 007-AM in CFBE cells. (A) 
Confocal live cell imaging analysis of GFP-EPAC1 in CFBE and HEK293 cells. For each cell, only 
images before and 6 minutes after addition of 1µM 007-AM are shown. Scale bars, 10 µm. (B) The 
bar graph shows the percentage of cells showing translocation of EPAC1 to the PM upon 007-AM 
stimulation
according to 75
. n=11-40. (C) The graphs show an illustrative fluorescence pixel intensity of 
GFP-EPAC1 at the PM versus cytosol during stimulation with 1µM 007-AM relative to pre-stimulus 
levels, calculated as described in Materials and Methods. Images were acquired every 3 min. 
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As shown by live cell imaging, EPAC1, that is mainly localized in the cytosol and around 
the nucleus under basal conditions, translocates to the PM after being activated with 007-
AM, in CFBE and HEK293 cells. This translocation occurs within the first 3 min of 
incubation with this cAMP analogue and it is independent of CFTR (Figure 3.2A). The 
Western Blot analysis after cell fractionation confirmed the translocation phenomenon for 
endogenous EPAC1, in CFBE cells. Additionally, the cellular distribution of EPAC1 
suggests that this protein and CFTR may co-localize or even interact with each other, 
mainly under 007-AM treatment. 
Although we have already shown that 007-AM induces a conformation change on camps 
and possibly the activation of endogenous EPAC, we don’t know yet if this analogue can 
induce the activation of one of the downstream effectors of EPAC, Rap, as a result of 
endogenous EPAC activation. To assess this question, CFBE cells were transfected with 
Raichu-Rap FRET sensor, a reporter of EPAC activity (described in section 2.4.1). 
Additionally, a pull-down based Rap activity assay (described in section 2.3.4) was also 
performed, with two objectives: to confirm that 007-AM promotes the activation of EPAC 
and to see if there is any difference in the levels of active EPAC in cells expressing WT- or 
F508del-CFTR (Figure 3.3). 
 
 
 
 
 
________________________________________________________________________ 
Figure 3.2 (continuation): 007-AM was added after the acquisition at minute 3. RFU, Relative 
Fluorescence Units. CFBE Parental – left plot; CFBE WT-CFTR – middle plot; CFBE F508del-
CFTR – right plot. (D) Western Blot showing the presence of endogenous EPAC1 in the membrane 
fraction after 30 min incubation with 1µM 007-AM (or DMSO as control) in CFBE cells. CFTR and 
TNF-R1 (Tumor Necrosis Factor Receptor 1) were used as PM markers; GAPDH (Glyceraldehyde 
3-phosphate dehydrogenase) was used as a cytosol marker. Whole cell lysates (WCL) were 
analyzed as controls. 
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The most evident result of Figure 3.3A is the fact that there is a higher FRET change at the 
PM for all cell lines. Theoretically, FRET changes are insensible to the concentration of 
FRET sensor at a certain region111. Thus, this may lead us to conclude that EPAC is 
mostly active at the PM. However, due to experimental artifacts like spectral overlap 
between donor and acceptor fluorophores (spectral bleed-through; SBT) this is not what 
we observe. SBT may refer to: part of the donor emission spectrum that overlaps with 
acceptor emission (donor SBT); part of the acceptor absorption spectrum that is excited by 
the donor wavelength (acceptor SBT)111. First of all, the PM localization of this FRET 
sensor can be explained by the fact that this sensor contains the full length of Rap, which 
has already been reported to localize at the PM due to CAAX motifs at their carboxyl 
termini that provide sites for lipid modification112-114. Thus, higher concentration of Raichu-
Rap at the PM may explain the higher FRET signal in this sub-cellular location. However, 
we can conclude that EPAC is active near the PM but not more active when compared to 
other cell compartments. To answer this question, it would be useful to use a Raichu-Rap 
FRET sensor without the PM-target domain (with cytosol localization). FLIM (Fluorescence 
lifetime imaging), a FRET method based on the fact that molecules doing FRET have 
shorter fluorescence lifetimes, could have been used because it is not affected by changes 
in probe concentration. However, this technique was not available at the time. 
________________________________________________________________________ 
Figure 3.3: Analysis of EPAC1 activation after treatment with 007-AM. (A) Analysis of Raichu-
Rap FRET sensor upon stimulation of CFBE cells with 1µM 007-AM. Intensity-modulated pseudo-
color images are shown here. For each cell, only images before and 30 minutes after addition of 
007-AM are shown. Scale bars, 10 µm. (B) Summary of all experiments performed in A, showing 
the fold increase in RFU of the FRET signal at the PM (as a percentage) 30 min after the addition of 
007-AM relative to pre-stimulus levels. ‘Baseline’ represents the value obtained if 007-AM does not 
induce a FRET change at the PM. Data represent means ± SEM. n = 24-45. (C, D) Western Blot 
showing the effect of 007-AM treatment upon the fraction of active Rap1A, in A549 or CFBE cells (C 
and D, respectively). Cells were incubated with 1µM 007-AM for 2h (or DMSO as control). (E) 
Quantification of fold increase of active Rap1A after treatment with 007-AM for A549 cells 
expressing WT- or F508del-CFTR. Amount of active Rap1A was normalized to the amount of total 
Rap1A and shown as fold change relatively to DMSO incubated cells. (F) Quantification of the ratio 
between active Rap1A in inducible A549 cells expressing F508del-CFTR versus cells expressing 
WT-CFTR. Data represent means ± SEM. n=3-4. *P<0.05; ***P<0.005. 
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Surprisingly, only CFBE cells stably expressing WT-CFTR show a FRET fold increase at 
the PM after treatment with 007-AM significantly different from the baseline (Figure 3.3B). 
Moreover, A549 or CFBE cells expressing F508del-CFTR tend to have higher levels of 
active Rap1A relative to cells expressing WT-CFTR (Figure 3.3 C, D and F). 007-AM 
treatment also seems to induce an increase of active Rap1A in A549 cells expressing WT-
CFTR but not in cells expressing F508del-CFTR (Figure 3.3E). One possible explanation 
to these observations is that cells expressing F508del-CFTR (or even cells that do not 
express CFTR at all) have higher levels of active EPAC (or active EPAC is closer to 
Rap1A). As a consequence, Rap activation cannot be increased so easily in these cells as 
in cells expressing WT-CFTR because they already have higher endogenous levels of 
active Rap.  
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3.2 Co-localization and interaction between CFTR and EPAC1 
To assess the co-localization between CFTR and EPAC1, confocal fluorescence 
microscopy was used. Hereupon, CFBE parental cells were co-transfected with mCherry-
CFTR (WT or F508del) and GFP-EPAC1 and live cell imaging was performed (Figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Analysis of CFTR and EPAC1 co-localization after treatment with 007-AM in CFBE 
cells. Confocal live-cell imaging analysis of (A) mCherry-WT-CFTR or (B) mCherry-F508del-CFTR 
and GFP-EPAC1 in CFBE cells. For each cell, only images before and 6 min after addition of 1µM 
007-AM are shown. Scale bars, 10 µm. (C) The bar graph shows the Pearson’s Coefficient analysis 
from A and B. Any value above the dotted line is considered to be significant for co-localization
106
. 
Data represent means ± SEM. n=9/18 (WT-CFTR/F508del-CFTR). *P<0.05; ***P<0.005. 
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As expected, WT-CFTR localizes at the PM while F508del-CFTR has a dispersed 
distribution within the cell. EPAC1 localizes in the cytosol, under pre-stimulus conditions, 
translocating to the PM after being activated with 007-AM, in CFBE cells overexpressing 
either WT- or F508del-CFTR. Thus, treatment with this cAMP analogue increases co-
localization between CFTR and EPAC1 (as assessed by Pearson’s Coefficient) in CFBE 
cells overexpressing WT-CFTR while it decreases this co-localization in CFBE cells 
overexpressing F508del-CFTR. For all conditions, there is a significant degree of co-
localization between CFTR and EPAC1. However, we must not confuse co-localization 
with physical interaction between proteins – co-localizing proteins may even be nowhere 
near each other. To prove that mCherry-CFTR and GFP-EPAC1 are close enough to 
interact, a photobleaching FRET approach (based on the fact that donor emission intensity 
will increase after acceptor photobleaching) was used because these fluorophores were 
already reported as a FRET pair115. However, no FRET was observed between these 
proteins (data not shown). One possible explanation is that the fluorophores are in 
opposite sides in this CFTR-EPAC1 complex, too far to allow energy transfer between 
them. It can also be explained by the method itself because for acceptor bleaching we 
need a strong and stable donor but not too bright in order to see any difference after 
photobleaching the acceptor. Other alternatives would be FLIM or sensitized emission 
FRET. However, this technique was not available at the time. Therefore, to evaluate the 
likely interaction between these two proteins, co-immunoprecipitation experiments were 
performed in CFBE and A549 cells (Figure 3.5). 
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Figure 3.5: Co-immunoprecipitation of CFTR and EPAC1. (A) Co-IP between GFP-EPAC1 and 
mCherry-WT-CFTR in transfected CFBE parental cells. Pull-down with beads only (without 
conjugated antibody) was used as a negative control. (B) Co-IP between CFTR and endogenous 
EPAC1 in CFBE cells stably expressing WT- or F508del-CFTR. (C) Co-IP between CFTR and 
endogenous EPAC1 in A549 cells overexpressing WT- or F508del-CFTR. Cells were treated with 
1µM 007-AM for 2h (or DMSO as control). (D) Quantification of CFTR-EPAC1 interaction fold 
increase after treatment with 007-AM in A549 cells overexpressing WT- or F508del-CFTR. Amount 
of precipitated CFTR or EPAC1 was normalized to the amount of immunoprecipitated EPAC1 or 
CFTR, respectively, and shown as fold change relatively to DMSO incubated cells. Data represent 
means ± SEM. n=3-5. *P<0.05; **P<0.01. 
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It was observed that GFP-EPAC1 co-immunoprecipitate with mCherry-WT-CFTR under 
basal conditions, suggesting that although the degree of co-localization under these 
conditions was near 0.5, these proteins can still interact with each other. To confirm this 
result, the same experiment was performed but this time using A549 or CFBE cells 
expressing WT- or F508del-CFTR. Besides showing that EPAC1 co-immunoprecipitates 
with WT-CFTR, the same result was observed for F508del-CFTR. This may indicate that 
EPAC1 can interact with CFTR even if this chloride channel is not at the PM, in early 
stages of CFTR trafficking. Additionally, incubation with 007-AM seems to promote the 
interaction between CFTR (WT or F508del) and EPAC1. This suggests that this interaction 
is promoted when EPAC1 is active. Based on these experiments we cannot conclude if the 
CFTR is only interacting with active EPAC1. Although an interaction between these 
proteins is still observed in the absence of 007-AM treatment, we do not know if 
endogenous levels of cAMP are enough to activate EPAC1 and promote its interaction 
with CFTR. Nevertheless, it seems that active EPAC1 interacts more easily with CFTR 
than inactive EPAC1. After being activated, EPAC1 translocates from the cytosol and 
perinuclear region to the PM vicinity which may facilitate the interaction with CFTR, mainly 
with WT-CFTR. This may explain the trend that 007-AM promotes more easily the 
interaction between EPAC1 and WT-CFTR compared to F508del-CFTR. From these 
experiments, we can also observe that EPAC activation does not affect total protein levels 
of CFTR and EPAC1, in cells expressing WT- or F508del-CFTR. The band C/band B ratio, 
indicative of the proportion of CFTR that has been correctly processed, is not affected by 
1µM 007-AM 2h treatment. It was also observed that 007-AM treatment does not affect the 
levels of total CFTR or the band C/band B ratio, relative to DMSO treatment, for 15min, 1, 
2, 4, 6, 24 and 48 h incubation period in CFBE cells stably expressing WT- or F508del-
CFTR (data not shown). 
Based on these results, we proposed that CFTR and EPAC1 may interact through a 
scaffold protein, like Ezrin or NHERF1, the later binding to CFTR PDZ binding domain. 
This was suggested mainly due to the fact that co-immunoprecipitation between EPAC1 
and CFTR was only detected in A549cells when EPAC1 was pulled-down. Although CFTR 
is a high molecular weight protein, an intermediate protein between EPAC1 and CFTR 
would help to explain this result, as EPAC has a lower molecular weight when compared 
to CFTR. In order to test this hypothesis, we used three different approaches: transient 
transfection of CFBE cells with siRNAs (Figure 3.6); Calu3 cells with stable knockdowns 
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using shRNAs (Figure 3.7); generation of a CFTR variant lacking the PDZ binding domain 
(∆TRL CFTR) (Figure 3.8). Then, co-immunoprecipitation assay was once again used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Co-immunoprecipitation of CFTR and EPAC1 in CFBE cells transiently 
transfected with siRNA against ezrin or NHERF1. (A) Co-IP between WT-CFTR and 
endogenous EPAC1 in CFBE cells stably expressing WT-CFTR. Non-targeting siRNA was used as 
siRNA control. (B) Amount of precipitated EPAC1 was normalized to the amount of 
immunoprecipitated CFTR, respectively, and shown as fold change relatively to siRNA control 
transfected cells. (C) Knockdown efficiency. Quantification of the amount of total Ezrin/NHERF1 
under transfection with siRNA (siRNA Ezrin and siRNA NHERF1, respectively), normalized to the 
amount of α-Tubulin/Calnexin and shown as fold change relatively to siRNA control transfected 
cells. Data represent means ± SEM. n=3. 
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Figure 3.7: Co-immunoprecipitation of CFTR and EPAC1 in Calu3 cells stably transfected 
with shRNA against ezrin or NHERF1. (A) Co-IP between endogenous WT-CFTR and EPAC1 in 
Calu3 cells stably transfected with shRNAs. Empty vector control without coding for any shRNA was 
used as shRNA control. (B) Amount of precipitated EPAC1 was normalized to the amount of 
immunoprecipitated CFTR, respectively, and shown as fold change relatively to shRNA control 
transfected cells. (C) Knockdown efficiency. Quantification of the amount of Ezrin or NHERF1 under 
transfection with shRNA (shEzrin or shNHERF1, respectively) relative to the amount of these 
proteins when shControl was used. Data represent means ± SEM. n=3. 
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Figure 3.8: Co-immunoprecipitation of GFP-EPAC1 
and WT- or ∆TRL-CFTR in CFBE cells. Co-IP between 
GFP-EPAC1 and WT- or ∆TRL-CFTR in co-transfected 
CFBE parental cells. Co-IP between CFTR and NHERF1 
was also performed to validate CFTR bearing the ∆TRL 
mutation. 
As observed in Figure 3.6 and Figure 3.7, NHERF1, but not Ezrin, knockdown, seems to 
abolish the interaction between EPAC1 and CFTR. Additionally, in Figure 3.7, co-IP 
between endogenous EPAC1 and endogenous CFTR was performed in Calu3 cells, 
confirming the interaction between CFTR and EPAC1 (as previously shown in Figure 3.5).  
It has been already reported that deletion of the TRL residues (1478-1480) in CFTR 
abolishes the interaction with the scaffolding protein NHERF127, 43. Thus, this mutation 
should also prevent CFTR-EPAC1 interaction if it is NHERF1-mediated. However, this was 
not observed. To confirm that ∆TRL-CFTR does not interact with NHERF1, this protein 
was also detected by Western Blot after CFTR pull-down. As seen in Figure 3.8, this 
mutation did not affect CFTR-NHERF1 interaction. Although ∆TRL-CFTR plasmid was 
sequenced after being generated to confirm the presence of this mutation, perhaps some 
mutations occurred during DNA amplification processes. Thus, ∆TRL-CFTR plasmid 
needs to be re-sequenced to confirm the presence of this mutation. Nevertheless, these 
three independent experiments that were performed seem to suggest that NHERF1, but 
not ezrin, mediates EPAC1-CFTR interaction. However, another possible hypothesis is 
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that NHERF1 may disrupt the sub-cellular localization of EPAC1, thus preventing its 
interaction with other proteins such as CFTR. To test this idea, fluorescence live-cell 
imaging was performed in Calu3 cells transfected with GFP-EPAC1 (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Analysis of EPAC1 localization after treatment with 007-AM in Calu3 cells. (A) 
Confocal live cell imaging analysis of GFP-EPAC1 in Calu3 cells. For each cell, only images before 
and 6 minutes after addition of 1µM 007-AM are shown. Scale bars, 10 µm. (B) The bar graph 
shows the percentage of cells showing translocation of EPAC1 to the PM upon 007-AM 
stimulation
according to 75
. n=9-15. 
 
EPAC1 sub-cellular localization or even its translocation to the PM after 007-AM treatment 
does not seem to be affected by ezrin or NHERF1 knockdown. This result was already 
anticipated because it has been already reported that cAMP regulates the binding of 
EPAC1 directly to phosphatidic acid at the PM108. Nevertheless, this observation is in 
agreement with the hypothesis that EPAC1-CFTR interaction is mediated by NHERF1. 
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3.3 Effect of EPAC1 on CFTR stability 
The next step was to evaluate the effect of EPAC activation/inhibition or EPAC1 
knockdown upon the stability of CFTR at the PM. To assess these, cell surface 
biotinylation and an endocytosis assay for CFTR were performed (Figure 3.10). 
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Figure 3.10:  CFTR surface expression and endocytosis under EPAC activation. (A) CFBE 
cells expressing WT-CFTR treated with 1μM 007-AM for 2h (or DMSO as control) were subjected to 
cell surface protein biotinylation, followed by incubation at 37ºC (during 2.5, 5 or 10 minutes). After 
that, cells were treated with a GSH solution and, following cell lysis, the obtained extracts were 
subjected to a streptavidin pull-down (described in section 2.3.6). Samples not treated with GSH 
were considered as a positive control. Samples not incubated at 37ºC were considered as a 
negative control. (B) Quantification of the percentage of internalized CFTR. From the amount of 
endocyted CFTR, - control was subtracted followed by a normalization to the + control. Data 
represent means ± SEM. n=3. (C) CFBE cells expressing WT-CFTR treated with 1μM 007-AM or 
5μM ESI-09 for 2h (or DMSO as control) were subjected to cell surface protein biotinylation. ESI-09 
has been reported as a EPAC specific inhibitor. Samples not treated with biotin were considered as 
a negative control. Additionally, CFBE cells expressing WT-CFTR were also transfected with 
siRNAs. Non-targeting siRNA was used as siRNA control. (D, F) Quantification of the amount of 
CFTR at the PM. Amount of CFTR at the PM was normalized to the amount of total CFTR and 
shown as fold change relatively to DMSO or siRNA control treated cells. Data represent means ± 
SEM. n=3. (E) Quantification of the amount of total CFTR normalized to the amount of Calnexin and 
shown as fold change relatively to DMSO incubated cells. Data represent means ± SEM. n=6. (G) 
Knockdown efficiency. Quantification of the amount of total EPAC1 normalized to the amount of 
Calnexin shown as fold change relatively to siRNA control. Data represent means ± SEM. n=3. 
**P<0.01; ***P<0.005. 
 
The endocytosis assay showed that EPAC activation promotes CFTR stability at the PM, 
decreasing the percentage of internalized CFTR over time (Figure 3.10A and B). In 
agreement with this result, activation of EPAC increased CFTR-PM steady-state levels 
(Figure 3.10C). Additionally, incubation of CFBE cells with ESI-09, an EPAC specific 
inhibitor116, 117, seems to decrease PM levels of CFTR, which would complement the 
previous results. However, when normalized to total CFTR, there is no significant 
difference between DMSO and ESI-09 treatment because this EPAC inhibitor also 
decreased the levels of total CFTR. This effect is CFTR-specific as total levels of EPAC1 
or calnexin were not affected by this inhibitor. However, it has been already suggested that 
ESI-09 may act as general protein denaturing agent and does not act on EPAC 
selectively118 – an observation that does not explain the absence of effect upon EPAC1 or 
calnexin levels. However, as CFTR is a large membrane protein that needs scaffolding 
proteins to be stable at the PM, it may be more affected by this compound than EPAC1 or 
Calnexin, which are not membrane and probably more stable proteins. Nonetheless, 
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EPAC1 knockdown using siRNAs decreased the levels of PM CFTR, which is in 
agreement with the previous experiments (Figure 3.10C, F and G). This approach allowed 
for discrimination between EPAC1 and EPAC2 and confirmed that EPAC-effect on CFTR 
stability is probably mediated by EPAC1; however, this result does not exclude the 
involvement of EPAC2 on CFTR regulation. So, all the results from this set of experiments 
suggest that EPAC1 promotes CFTR stability at the PM. 
Nonetheless, the observed effect may result from promotion of CFTR traffic towards the 
PM or from CFTR increased stability at the PM (decreased endocytosis and/or reduced 
recycling). Therefore, we used an alternative approach to evaluate the effect of EPAC1 
upon CFTR stability. This time, we wondered if EPAC1 overexpression could promote 
newly synthetized-CFTR stability. For this, CFBE Parental cells were transiently co-
transfected with mCherry-WT-CFTR and GFP or GFP-EPAC1 and the levels of CFTR 
were assessed by WB at specific time points after incubation with cycloheximide (Figure 
3.11). 
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Figure 3.11: Effect of EPAC upon CFTR stability. CFBE Parental cells transiently co-transfected 
with mCherry-WT-CFTR and GFP or GFP-EPAC1 were treated with 10µg/mL of cycloheximide for 
1, 2 or 5h, 24 or 48 h after transfection. Cycloheximide was used as an inhibitor of protein 
biosynthesis. Cells not transfected with GFP or GFP-EPAC1 were also not transfected with 
mCherry-WT-CFTR. Because the amount of CFTR used to transfect cells for each condition is of 
extremely importance, all transfection solutions were prepared starting from the same solution to 
avoid human error.  
 
Interestingly, GFP-EPAC1 overexpression seems to promote CFTR stability relative to 
GFP overexpression. This new data complements the previous results, strengthening the 
hypothesis that EPAC1 may promote CFTR stability at and before reaching the PM. 
Although we cannot drain any conclusion from this single experiment, overall, EPAC1 
appear to effect CFTR stability. Surprisingly, results from quantitative PCR (data not 
shown) seem to indicate lower amount of CFTR transcripts in cells incubated with 007-AM 
(relative to DMSO). Because this compound does not affect the total protein levels of 
CFTR, this result may also suggest that EPAC1 activation promotes CFTR stability. 
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Additionally, we wondered if VX-809-induced rescue of F508del-CFTR can be improved by 
EPAC activation. To answer this question, a Western Blot methodology was used (Figure 
3.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Effect of 007-AM upon F508del-CFTR rescue. (A) CFBE cells expressing F508del-
CFTR were treated with 1µM 007-AM, 3µM VX-809 (a compound that corrects the trafficking defect 
of F508del-CFTR; Selleckchem) or both (DMSO was used as a negative control) for 24 or 48h. (B) 
Quantification of the percentage of rescued CFTR. The amount of band C was normalized to the 
total amount of CFTR (band C + band B). This ratio obtained was normalized to the WT ratio and 
the result was express as a percentage. (C) The values obtain from C are shown as a fold increase 
relatively to VX-809 treated cells. Data represent means ± SEM. n=8-10. *P<0.05. 
 
The combined effect of VX-809 and 007-AM tends to improve F508del-CFTR rescue 
relative to VX-809 treatment – suggesting that targeting of CFTR membrane stability 
through EPAC activation may be an approach to use in combinatorial treatment with the 
corrector.  
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3.4 Effect of CFTR upon EPAC-induced cell adhesion 
The last goal was to evaluate the effect of CFTR on EPAC-promoted biological function. 
One of the major biological roles of EPAC is the regulation of cell to cell or cell to matrix 
adhesion47. Thus, we performed a cell adhesion assay to evaluate if the presence of 
F508del-CFTR could affect this process in comparison to WT-CFTR (Figure 3.13). 
 
 
 
 
 
 
 
 
Figure 3.13: Effect of CFTR upon EPAC-induced cell adhesion. CFBE cells expressing (A) WT- 
or (B) F508del-CFTR were treated with 1µM 007-AM or 5µM ESI-09 (DMSO was used as a control) 
for 2h. Cells were allowed to attach to a coated surface for 30, 60 or 180 minutes (described in 
section 2.5.1). The results are expressed as percentage of cells that attached to the surface (ratio 
between If after washing/ If before washing) over time. Data represent means ± SEM. n=20-30. 
 
As expected, the more time cells had to attach to the surface, higher the percentage of 
adherent cells. Moreover, CFBE cells expressing F508del-CFTR seem to attach badly to 
the plate surface comparing to CFBE cells expressing WT-CFTR. Additionally, ESI-09 
treatment decreases the percentage of cells that attached to the surface.  
The most interesting result was the fact that 007-AM seems to promote cell adhesion in 
CFBE cells expressing WT-CFTR but not in CFBE cells expressing F508del-CFTR. This 
suggests that lower amounts of CFTR at the PM somehow abolish the activation of EPAC 
downstream effectors and consequent promotion of cell adhesion. 
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4. Discussion and Perspectives 
Ion transport through CFTR is stimulated when cAMP levels in the subcortical 
compartment increase leading to PKA activation, thus triggering CFTR phosphorylation 
and channel opening. However, PKA is not the only cAMP sensor within the cell. EPAC, 
an exchange protein directly activated by cAMP, is another more recently discovered 
cAMP effector47, 48, 50. 
EPAC proteins are mainly known for their function as guanine nucleotide exchange factor 
for Rap, a small Ras-like GTPase51. It has been reported that EPAC is involved in the 
regulation of cell-to-cell and cell-matrix adhesion, cytoskeleton rearrangements and cell 
polarization47, 48, 82, 119. Interestingly, all these processes are involved in CFTR regulation. 
Moreover, since cytoskeleton proteins have an important role in tethering CFTR to the 
plasma membrane, this is a process in which EPAC can affect CFTR steady-state 
membrane levels. Moreover, Rap signaling has a known role in E-cadherin recycling via 
Rab11-positive vesicles and CFTR recycling also requires Rab11-containing vesicles23. 
Since CFTR recycling regulates the amount of protein at the plasma membrane, EPAC via 
Rap may also regulate this process. Additionally, EPAC1, an EPAC isoform, shifts to the 
plasma membrane in response to a cAMP-induced conformational change74. EPAC1 is 
activated by stimuli that result in increased subcortical cAMP, the same stimuli that induce 
PKA-mediated activation of CFTR. This makes plausible that activation of both CFTR and 
EPAC might be spatially and temporally coincident. All this data supports the hypothesis 
that EPAC1 has a potential effect on CFTR trafficking and PM anchoring. However, the 
possible connection between these proteins has never been studied. 
Thus, this work was based on the hypothesis that EPAC1, the only EPAC isoform whose 
conformation and translocation are cAMP-dependent, could be a new link between this 
second messenger and CFTR regulation. Therefore, the aim of the present work was to 
study the interaction between CFTR and EPAC1 and to evaluate the impact of this cAMP 
effector on CFTR biogenesis, trafficking and PM anchoring. 
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4.1 Effect of 007-AM treatment on EPAC1 
The first objective was to evaluate the effect of the compound 007-AM treatment on EPAC 
tertiary structure, sub-cellular localization and activity. This allows confirmation of this 
compound as an EPAC specific agonist. This and the following studies were performed 
mainly in CFBE cells to better mimic the processes that occur in the bronchial epithelium 
of CF patients with F508del mutation. Adenocarcinoma cells, such as Calu3 and A549 
cells, were also used, as they are also good cell models to study the airways. 
FRET analysis of cAMP levels and PKA activity, using camp or AKAR4 FRET sensors, 
respectively, showed a high percentage of FRET change for camps compared to the small 
FRET change observed for AKAR4, after adding 007-AM. This confirmed 007-AM as an 
EPAC specific agonist and validated the concentration of this compound used for this work 
(1µM). EPAC1 translocation to the plasma membrane after 007-AM treatment was 
observed in CFBE cells and found to be independent of CFTR, as assessed by confocal 
fluorescence microscopy. This was already expected since EPAC translocates to the PM 
by a phosphatydic acid- or ERM proteins-dependent way75, 76. However, this does not 
exclude a possible interaction between EPAC1 and CFTR. Instead, EPAC1 cellular 
distribution suggests that this protein and CFTR may co-localize or even interact with each 
other, mainly under 007-AM treatment as EPAC1 is relocated to the PM.  
Additionally, activity of endogenous EPAC was studied using Raichu-Rap FRET sensor 
and a pull-down based Rap activity assay. Interestingly, only cells expressing WT-CFTR 
showed a FRET fold increase at the PM after treatment with 007-AM, while cells 
expressing F508del-CFTR tend to have higher levels of active Rap1A. 007-AM treatment 
also leads to an increase the levels of active Rap1A in cells expressing WT-CFTR but not 
in cells expressing F508del-CFTR. One possible explanation for these observations is that 
cells expressing F508del-CFTR (and probably cells that do not express CFTR) have 
higher levels of active EPAC or alternatively active EPAC is closer to Rap1A. 
Consequently, Rap activation cannot be increased so easily in these cells as in cells 
expressing WT-CFTR, since they already have higher endogenous levels of active Rap. 
This may suggest that EPAC-Rap pathway is not able somehow to exert its function and, 
in order to try to compensate and overcome this situation, a negative feedback loop 
promotes EPAC activation in cells expressing F508del-CFTR.  
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Following this idea, it would be interesting to follow this pathway and see if there are any 
proteins or even transcription factors downstream EPAC differentially regulated/expressed 
in cells expressing WT- or F508del-CFTR. Ideally, a protein whose regulation is affected 
by the presence of CFTR at the PM would be identified. 
 
4.2 Co-localization and interaction between CFTR and EPAC1 
EPAC1 co-localizes with both WT- or F508del-CFTR, in CFBE cells without stimulus or 
under 007-AM treatment. Additionally, these proteins co-immunoprecipitate in CFBE, A549 
and Calu3 cells. The fact that EPAC1 interaction is also detected with F508del-CFTR 
suggests that this interaction may occur at the early stages of CFTR trafficking, when this 
chloride channel is not at the PM. However, it remains to be further clarified at which 
phase of CFTR trafficking these proteins interact. Co-IP after cell fractionation was 
performed but the output was inconclusive. Moreover, EPAC activation promotes CFTR-
EPAC1 interaction, which suggests that this interaction is promoted when EPAC1 is active. 
However, it remains to be elucidated if inactive EPAC1 can interact with CFTR. Although 
without 007-AM treatment co-IP between these proteins is achieved, endogenous levels of 
cAMP may be enough to activate EPAC and promote its interaction with CFTR – even if 
EPAC1 is not clearly at the PM under basal conditions in CFBE or Calu3 cells, as detected 
by confocal fluorescence microscopy. To address this question, the same experiments 
could have been performed in the presence of indomethacin (depleting endogenous cAMP 
levels). Nevertheless, it seems that active EPAC1 interacts more easily with CFTR than 
inactive EPAC1.  
This increased interaction under EPAC activation may result from different molecular 
events: 
- EPAC1 suffers a conformational change;  
- EPAC1 translocates to the PM;  
- EPAC1 becomes catalytically active (or combination of several options). 
This question can be assessed by using EPAC1 mutants without the DEP domain 
(required for cAMP-induced translocation of EPAC1), mutated in the CNB (cyclic 
nucleotide–binding) domain (to prevent cAMP-induced conformation change) or 
catalytically dead mutants (mutated in the catalytic region). 
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After being activated, EPAC1 translocates from the cytosol and perinuclear region to the 
PM vicinity, which may facilitate the interaction with CFTR, mainly with WT-CFTR. This 
may explain why 007-AM promote more easily the interaction between EPAC1 and WT-
CFTR compared to EPAC1 and F508del-CFTR. Moreover, EPAC activation does not 
affect the band C/band B ratio, indicative of the proportion of CFTR that has been correctly 
processed, suggesting that EPAC is not involved in the early stages of CFTR biogenesis, 
such as folding and processing of this chloride channel. 
On the other hand, NHERF1, but not ezrin, knockdown (through siRNA or shRNA 
transfection) prevented CFTR-EPAC1 interaction without disrupting EPAC1 sub-cellular 
localization. Thus, EPAC1 may interact with CFTR through the NHERF1 mediator. This is 
somehow expected as NHERF1 is a protein adapter highly expressed in epithelial tissues 
with the ability to bring together membrane and non-membrane proteins to regulate cell 
metabolism and growth120. However, to confirm this result, co-IP between EPAC1 and 
∆TRL-CFTR needs to be redone after confirming the sequence of this plasmid. 
Additionally, the role of the structurally related protein E3KARP (NHE3 kinase A regulatory 
protein or NHERF2) in CFTR-EPAC1 interaction remains to be clarified, since both 
NHERFs have already been reported to interact with CFTR120. This could be done using 
the same approach used for NHERF1. Based on our results, it is likely that EPAC1 
physically interacts with NHERF1, although EPAC1-NHERF1 interaction has not been 
shown yet. This needs to be assessed in the near future. 
Both NHERF1 and NHERF2 have two PDZ domains and both bind to CFTR27, 121. It has 
also been suggested that ezrin can positively regulate the cooperative binding of NHERF 
to C-terminus of CFTR. As a result of ezrin binding, a specific ternary complex (CFTR)2-
NHERF-Ezrin of 2:1:1 stoichiometry is formed, in which two CFTR molecules are anchored 
to NHERF122. Moreover, it would also be interesting to see which NHERF1 domain is 
involved in EPAC1-CFTR interaction. This could be tested using GST fusion proteins, with 
each PDZ domain of NHERF1, immobilized on glutathione-agarose beads, as has been 
already reported121, or using NHERF1 mutated in its PDZ domains. Nevertheless, one 
possibility is that NHERF1 interacts simultaneously with CFTR and EPAC1, through its 
PDZ domains, and with ezrin through its carboxyl terminus (the later may also tether PKA). 
The generation of a macromolecular complex also involving cytoskeleton proteins may 
play a key role in fine-tuning the regulation of CFTR stability and function, as has been 
suggested123. 
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EPAC1 or EPAC2 (UniProtKB accession numbers O95398 and Q8WZA2, respectively) do 
not contain a PDZ domain within their sequence, supporting the need of an adaptor protein 
between CFTR and EPAC1, since EPAC probably cannot bind directly to CFTR C-
terminus124. Nevertheless, several hits were identified for both EPACs accordingly to the 
consensus sequence of the PDZ binding domain (C-terminal X-[S/T]-X-[V/I/L])24, as 
assessed by ScanProsite tool125. However, a more stringent consensus sequence of PDZ 
binding domain has been published: [S/T]-[R/Y]-L-COOH for NHERF PDZ1 domain and S-
[S/T]-W-L-COOH for NHERF PDZ2 domain25. Using PDZ1 consensus sequence, we 
identified 3/2 hits for EPAC1/EPAC2, while using PDZ2 consensus sequence no hit was 
identified (Table 4.1). Interestingly, only EPAC1 has a putative PDZ1 binding domain 
(residues SRL) at its C-terminus. To validate these hypotheses, EPAC mutants could be 
generated and tested by co-IP with CFTR. Nonetheless, this is in agreement with the 
previous hypothesis of a macromolecular complex involving CFTR, NHERF1, Ezrin, PKA 
and EPAC1. 
Without ezrin, the PDZ2 domain of NHERF is inhibited. Binding of ezrin to NHERF 
promotes a conformational change exposing the PDZ2 domain126. If binding of EPAC1 to 
NHERF was PDZ2 mediated, ezrin knockdown would abolish this interaction - however, 
this is not what we observe. Thus, this suggests that the interaction between EPAC1 and 
NHERF may be mediated by PDZ1 domain (Figure 4.1). 
 
Table 4.1: Hits for PDZ1 consensus sequence on EPAC1 and EPAC2 sequences. 
 
Proteins (length) Residues Position 
EPAC1 (923) 
TRL 501-503 
SRL 767-769 
SRL 915-917 
EPAC2 (1011) 
TRL 36-38 
SRL 876-878 
 
  
Chapter IV 
70 
 
4.3 Effect of EPAC1 on CFTR stability 
The endocytosis assay showed that EPAC activation promotes CFTR stability at the PM, 
decreasing the amount of internalized CFTR over time. Moreover, 007-AM treatment 
increased CFTR-PM steady-state levels while EPAC1 knockdown by siRNA decreased 
these levels. This approach allowed for discrimination between EPAC1 and EPAC2 and 
confirmed that EPAC-effect on CFTR stability is probably mediated by EPAC1. However, 
this result does not exclude the involvement of EPAC2 on CFTR regulation. To assess this 
question, an EPAC2 specific inhibitor, such as ESI-05 or ESI-07, could be used for the 
biotinylation or endocytosis assay118, 127. Nevertheless, interaction of EPAC1 with CFTR 
promotes the stability of this chloride channel at the PM.  
GFP-EPAC1 overexpression seems to promote CFTR stability relative to GFP 
overexpression. Additionally, combined effect of VX-809 and 007-AM tends to improve 
F508del-CFTR rescue relative to VX-809 treatment. Altogether, these results enforce the 
hypothesis that EPAC1 promotes CFTR stability at and before reaching the PM, and also 
suggest that modulation of the EPAC pathway may be followed as an additional strategy 
for the functional correction of F508del-CFTR.  
Results from quantitative PCR show a reduced amount of CFTR transcripts in cells 
incubated with 007-AM (relative to DMSO). Because this compound does not affect the 
total protein levels of CFTR, this result may also suggest that EPAC1 activation promotes 
CFTR stability. However, we do not know yet if this is a result of an EPAC1 downstream 
effector or of EPAC1 protein itself. To test this, a catalytically dead EPAC1 mutant can be 
used. It would be also interesting to use a pulse-chase approach to evaluate the impact of 
EPAC1 on CFTR trafficking to the PM.  
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Figure 4.1: Model of CFTR-EPAC1 interaction. Binding of CFTR to NHERF1 anchors the channel 
(via Ezrin) to the actin cytoskeleton. In cells with low levels of cAMP (A), EPAC1 is inactive and its 
interaction with CFTR is not promoted. In cells with high levels of cAMP (B), both PKA and EPAC1 
are active, promoting the opening of the channel and stabilizing CFTR at the PM, respectively. PDZ 
- PSD95, Dlg1, ZO-1 binding motif.  
Cl- A B 
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4.4 Effect of CFTR upon EPAC-induced cell adhesion 
The cell adhesion assay showed that CFBE cells expressing F508del-CFTR seem to 
attach less to the plate surface comparing to CFBE cells expressing WT-CFTR. Moreover 
007-AM promotes cell adhesion in CFBE cells expressing WT-CFTR but not in CFBE cells 
expressing F508del-CFTR. This suggests that lower amounts of CFTR at the PM 
somehow abolish the activation of EPAC downstream effectors and consequent promotion 
of cell adhesion. However, the mechanism or pathway responsible for this observation is 
still unknown. Nevertheless, this result corroborates the hypothesis (section 4.1) that, in 
cells expressing F508del-CFTR, EPAC-Rap pathway is not able to exert its function and, 
in order to try to compensate and overcome this problem, a negative feedback loop 
promotes EPAC activation. It would be of major interest to perform more experiments to 
confirm and understand how CFTR can affect EPAC, as these results suggest. 
Despite the recent advances in the CF field, there are still major aspects of its 
traffic/activation which remain to be solved and key intervenients in these processes which 
remain unidentified. The present work unveiled a new relationship between CFTR and the 
cAMP effector EPAC1.  
In summary, here we confirmed 007-AM as an EPAC specific agonist that induces a 
conformational change and translocation of EPAC1 to the PM. Unexpectedly, cells 
expressing F508del-CFTR seem to have higher levels of active EPAC and Rap1A. On the 
other hand, EPAC1 and CFTR co-localize and physically interact through the protein 
adaptor NHERF1. Finally, EPAC activation promotes this interaction and CFTR stability. 
Thus, this work constitutes an important characterization of a new CFTR interacting 
protein that links cAMP signaling to Cystic Fibrosis modulation in a previously unreported 
mechanism.  
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4.5 Future Perspectives 
The results obtained suggest a deeper characterization of the cross-talk between CFTR 
and EPAC. To better understand the mechanism underneath this relationship, the 
regulatory pathways already known for both proteins and common points need to be 
further studied, in order to establish new experimental procedures that will also help to 
clarify some of the results observed. 
Besides all the future studies already suggested (section 3 and 4), several experiments 
remain to be performed. It would be interesting to evaluate if EPAC2 also interacts with 
CFTR and to study the impact of EPAC2 on CFTR stability, using the same approaches 
that have been used. For this, siRNA against EPAC2, specific inhibitors (such as ESI-05) 
or activators (such as sulfonylurea) would be of great interest.  
To reinforce that all the results observed are a result of the impact of EPAC on CFTR 
stability, a PKA specific agonist can be also used as a control. 
Cell polarization is characterized by a selective distribution of membrane proteins among 
the apical and basolateral sides – CFTR trafficking to the PM is dependent on the cell 
polarization state85, 86. Thus, confocal fluorescence microscopy and co-IP assays to 
evaluate EPAC1 and CFTR co-localization or physical interaction could be performed in 
polarized CFBE cells or even in freshly isolated bronchial/tracheal/nasal epithelial primary 
cells. This more biological relevant model would add a new layer of complexity since this 
relationship may also be dependent on cellular polarization. 
It has been shown that EPAC is involved in cAMP-stimulated Cl− secretion but not through 
CFTR128. Nonetheless, it would be interesting to complement our results to evaluate the 
impact of EPAC on CFTR function using electrophysiological approaches such as iodide 
efflux assays, Ussing chamber or Patch Clamp experiments. 
Additionally, generation of new cell systems with inducible EPAC1 and EPAC2 expression 
would allow a more detailed characterization of EPAC impact on CFTR stability and 
function.  
Finally, electron microscopy combined with fluorescence microscopy using EPAC tagged 
with APEX (a tag based on Horseradish peroxidase) and a fluorophore could be used to 
better evaluate EPAC localization before and after 007-AM stimulus in polarized cells129. 
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pEGFP-C2 plasmid map 
 
 
pCAGGS plasmid map 
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Forskolin standard curve for AKAR4 and camp FRET sensors 
 
To evaluate the dynamic range of AKAR4 and camp FRET sensor, a forskolin standard 
curve was performed (Figure 1). 
 
 
Figure 1: Frsk standard curve for AKAR4 and camp FRET sensors. It was used to evaluate the 
dynamic range of AKAR4 and camps. Percentage of FRET change is the normalized 545nm/408nm 
value calculated at each acquisition time point for each Frsk concentration (0.1, 1, 10 and 25µM). 
 
Sequential increases in Frsk caused a rapid increase in FRET and subsequent apparent 
saturation of the response in the PKA sensor, whereas the EPAC sensor changed more 
gradually and showed a larger dynamic range. This is in agreement with data already 
published89. 
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Preparation of GST-RalGDS-RBD-coupled beads for Rap1A activity assay 
 
GST-RalGDS-RBD-coupled beads were produced for the Rap1A activity assay. To 
confirm the expression of the recombinant protein by bacteria transformed with pGEX-
GST-RalGDS-RBD-GST, aliquots of bacteria were taken immediately before and after 4h 
incubation with IPTG, centrifuged at 4000g for 10min and lysed in sample buffer. Extracts 
were run on an SDS-PAGE gel, which was then stained with Coomassie Blue (Figure 2). 
The appearance of a strong band below the 37kDa marker confirmed the expression of 
recombinant protein. 
However, it was still necessary to know how much glutathione-coupled agarose beads 
should be added to the bacterial extracts in order to prepare the final beads (GST-
RalGDS-RBD-coupled). For this, the amount of recombinant protein recovered was 
predicted by running simultaneously on the same SDS-PAGE gel increasing amounts of 
BSA along with an aliquot of the bacterial extract (Figure 2). 
 
 
 
 
 
 
 
 
Figure 2: Expression of GST-RalGDS-RBD recombinant protein after induction with IPTG. 
Coomassie-stained SDS-PAGE gel used to quantify the amount of recombinant protein expressed. 
 
A standard curve was made using BSA bands intensities (Figure 3). 
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Figure 3: BSA standard curve for the SDS-PAGE gel. It was used to quantify the amount of 
recombinant protein present in the bacterial extracts. AU, Arbitrary Units. 
 
Lastly, this standard curve was used to determine the amount of protein in the bacterial 
extracts, yielding a value of 1.106 mg of recombinant protein per mL. 1mL of GSH-beads 
slurry was added to 6mg of protein (according to the manufacturer’s instructions) and for 
2h at 4ºC. GST-RalGDS-RBD-coupled beads were then washed and stored at -20ºC. To 
confirm that the recombinant protein was attached to the beads, several aliquots of beads 
were run on an SDS-PAGE gel (Figure 4). 
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Figure 4: GST-RalGDS-RBD recombinant protein attached to agarose beads. Aliquots of 
bacteria taken before and after induction were used as negative and positive control, respectively. 
 
GST-RalGDS-RBD-coupled beads were confirmed by the appearance of a strong band 
near the 37kDa marker. 
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Fluorescence intensity and number of cells correlation 
 
To ensure that there was a linear correlation between fluorescence intensity and number 
of cells stained with Hoechst 33342, a standard curve was made for each 96-well plate 
used (Figure 5) 
 
 
 
 
 
 
Figure 5: Fluorescence intensity against number of cells. Average of standard curves for CFBE 
cells stably expressing (A) WT- or (B) F508del-CFTR. Data represent means ± SEM. n = 4/6 
(F508del-/WT-CFTR). 
 
A linear correlation between fluorescence intensity and number of cells was confirmed for 
CFBE cells expressing WT- or F508del-CFTR, confirming the method’s robustness. 
  
  
 
  
 
  
 
